var title_f18_11_18608="Dx back pain in cancer";
var content_f18_11_18608=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 565px\">",
"   <div class=\"ttl\">",
"    Diagnostic approach to back pain in patients with cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 545px; height: 463px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     XRT: radiation therapy.",
"     <br>",
"      * Combined CT and myelogram may be used in place of MRI if MRI is unavailable or contraindicated.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_11_18608=[""].join("\n");
var outline_f18_11_18608=null;
var title_f18_11_18609="Sex reversal";
var content_f18_11_18609=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sex reversal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patient with male phenotypic appearance had a 46,XX karyotype and sex reversal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy Christopher P Houk, MD and Lynne L Levitsky, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_11_18609=[""].join("\n");
var outline_f18_11_18609=null;
var title_f18_11_18610="Cloacal malformation";
var content_f18_11_18610=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cloacal malformation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transverse view of fetal abdomen at gestational age of 21 weeks shows a distended loop of bowel (arrows) with echogenic debris, some of which is calcified. A loop of bowel containing calcifications and located in the midabdomen/pelvis is a marker for cloacal malformation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_11_18610=[""].join("\n");
var outline_f18_11_18610=null;
var title_f18_11_18611="Patient information: Colonoscopy (The Basics)";
var content_f18_11_18611=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15413\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/46/4834\">",
"          Colonoscopy",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?18/53/19281\">",
"         Patient information: Anemia caused by low iron (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?41/29/42450\">",
"         Patient information: Bloody stools (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/63/10227\">",
"         Patient information: Cancer screening (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/27/19890\">",
"         Patient information: Colon and rectal cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/5/9298\">",
"         Patient information: Colon polyps (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/31/22002\">",
"         Patient information: Gas and bloating (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/24/25986\">",
"         Patient information: Stomach ache and stomach upset (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?7/23/7541\">",
"         Patient information: Colon and rectal cancer screening (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/9/25747\">",
"         Patient information: Colon polyps (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/30/9698\">",
"         Patient information: Colonoscopy (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Colonoscopy (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/colonoscopy-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H460793102\">",
"      <span class=\"h1\">",
"       What is a colonoscopy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A colonoscopy is a test that looks at the inside lining of a person&rsquo;s large intestine. The large intestine is also called the colon (",
"      <a class=\"graphic graphic_figure graphicRef66110 \" href=\"UTD.htm?28/27/29107\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Often, people have colonoscopy as a screening test to check for cancer in the colon or rectum. People can also have colonoscopy if they have any of the symptoms listed below. Cancer screening tests are tests that are done to try and find cancer early, before a person has symptoms. Cancer that is found early often is small and can be cured or treated easily.",
"     </p>",
"     <p>",
"      Doctors can use 5 or 6 different tests to screen for colon cancer. But most doctors think that colonoscopy is the best test to screen for colon cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H460793109\">",
"      <span class=\"h1\">",
"       When should I have colon cancer screening?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors recommend that most people begin having colon cancer screening at age 50. Some people have an increased chance of getting colon cancer, because of a strong family history or certain medical conditions. These people might begin screening at a younger age.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H460793116\">",
"      <span class=\"h1\">",
"       What are other reasons my doctor might order a colonoscopy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor might order a colonoscopy if you have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood in your bowel movements",
"       </li>",
"       <li>",
"        A change in your bowel habits",
"       </li>",
"       <li>",
"        A condition called anemia that can make you feel tired and weak",
"       </li>",
"       <li>",
"        Long-term belly or rectal pain that you cannot explain",
"       </li>",
"       <li>",
"        Abnormal results from a different type of colon test",
"       </li>",
"       <li>",
"        A history of colon cancer or growths in your colon",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H460793123\">",
"      <span class=\"h1\">",
"       What should I do before a colonoscopy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor will give you instructions about what to do before a colonoscopy. He or she will tell you what foods you can and cannot eat. He or she will also tell you if you need to stop taking any of your usual medicines beforehand.",
"     </p>",
"     <p>",
"      The colon needs to be cleaned out before a colonoscopy. Your doctor will give you a pill or special drink that causes watery diarrhea. Let your doctor know if you have trouble getting ready for your colonoscopy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H460793130\">",
"      <span class=\"h1\">",
"       What happens during a colonoscopy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor will give you medicine to make you feel relaxed. Then he or she will put a thin tube with a camera and light on the end into your anus and up into the rectum and colon (",
"      <a class=\"graphic graphic_figure graphicRef52258 \" href=\"UTD.htm?4/46/4834\">",
"       figure 2",
"      </a>",
"      ). Your doctor will look at the inside lining of the whole colon.",
"     </p>",
"     <p>",
"      During the procedure, your doctor might do a test called a biopsy. During a biopsy, a doctor takes a small piece of tissue from the colon. Then he or she looks at the tissue under a microscope to see if it has cancer. Your doctor might also remove growths that he or she sees in the colon.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H460793137\">",
"      <span class=\"h1\">",
"       What happens after a colonoscopy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor will give you instructions about what to do after a colonoscopy. Most people can eat as usual. But most doctors recommend that people do not drive or go to work for the rest of the day.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H460793144\">",
"      <span class=\"h1\">",
"       When should I call my doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Call your doctor or nurse immediately if you have any of the following problems after your colonoscopy:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Belly pain that is much worse than gas pain or cramps",
"       </li>",
"       <li>",
"        A bloated and hard belly",
"       </li>",
"       <li>",
"        Vomiting",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        A lot of bleeding from your anus",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H460793151\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9298?source=see_link\">",
"       Patient information: Colon polyps (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=see_link\">",
"       Patient information: Cancer screening (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/29/42450?source=see_link\">",
"       Patient information: Bloody stools (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/31/22002?source=see_link\">",
"       Patient information: Gas and bloating (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/24/25986?source=see_link\">",
"       Patient information: Stomach ache and stomach upset (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/53/19281?source=see_link\">",
"       Patient information: Anemia caused by low iron (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/27/19890?source=see_link\">",
"       Patient information: Colon and rectal cancer (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=see_link\">",
"       Patient information: Colonoscopy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=see_link\">",
"       Patient information: Colon and rectal cancer screening (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/9/25747?source=see_link\">",
"       Patient information: Colon polyps (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?18/11/18611?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15413 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-4838B967EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_11_18611=[""].join("\n");
var outline_f18_11_18611=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H460793102\">",
"      What is a colonoscopy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H460793109\">",
"      When should I have colon cancer screening?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H460793116\">",
"      What are other reasons my doctor might order a colonoscopy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H460793123\">",
"      What should I do before a colonoscopy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H460793130\">",
"      What happens during a colonoscopy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H460793137\">",
"      What happens after a colonoscopy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H460793144\">",
"      When should I call my doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H460793151\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15413\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/46/4834\">",
"       Colonoscopy",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/53/19281?source=related_link\">",
"      Patient information: Anemia caused by low iron (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/29/42450?source=related_link\">",
"      Patient information: Bloody stools (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=related_link\">",
"      Patient information: Cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/27/19890?source=related_link\">",
"      Patient information: Colon and rectal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=related_link\">",
"      Patient information: Colon and rectal cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/9/25747?source=related_link\">",
"      Patient information: Colon polyps (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9298?source=related_link\">",
"      Patient information: Colon polyps (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=related_link\">",
"      Patient information: Colonoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/31/22002?source=related_link\">",
"      Patient information: Gas and bloating (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/24/25986?source=related_link\">",
"      Patient information: Stomach ache and stomach upset (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_11_18612="Pimecrolimus: Pediatric drug information";
var content_f18_11_18612=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pimecrolimus: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"    see \"Pimecrolimus: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/7/3189?source=see_link\">",
"    see \"Pimecrolimus: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F209930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Elidel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F209931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Elidel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Immunomodulating Agent, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"      see \"Pimecrolimus: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;2 years of age and Adults: Topical: Apply twice daily; use smallest amount of cream needed to control symptoms; continue therapy for as long as symptoms persist; re-evaluate patient at 6 weeks.",
"     <b>",
"      Note:",
"     </b>",
"     Pimecrolimus is not approved for use in children &lt;2 years of age since the drug's long-term effect on the developing immune system is unknown. Detectable blood levels were observed in a higher proportion of children as compared to adults and may be due to the larger surface area to body mass ratio seen in pediatric patients. Children &lt;2 years of age treated with pimecrolimus had a higher rate of upper respiratory infections than those treated with placebo.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F209917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elidel&reg;: 1% (30 g, 60 g, 100 g) [contains benzyl alcohol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F209905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088587.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088587.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1049371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Avoid contact with eyes, nose, mouth, and cut, scraped, or infected skin areas. Wash hands with soap and water prior to and after cream application. If applying cream after a bath or shower, make sure skin is dry. Apply thin layer of cream by gently rubbing it in over affected skin surfaces which may include head and neck areas. The use of occlusive dressings is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1049364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature; do not freeze",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Second-line agent for short-term and intermittent treatment of mild to moderate atopic dermatitis in nonimmunocompromised patients unresponsive to, or intolerant of other treatments",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7898347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Pimecrolimus may be confused with tacrolimus",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F209951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, folliculitis, herpes simplex dermatitis, impetigo, molluscum contagiosum, skin infection, skin papilloma (warts), urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, diarrhea, gastroenteritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning at application site (tends to resolve/improve as lesions resolve), erythema at application site, irritation at application site, pruritus at application site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Eye infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Ear infection, otitis media",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma, asthma aggravated, bronchitis, cough, dyspnea, epistaxis, nasal congestion, nasopharyngitis, pharyngitis, pneumonia, rhinorrhea, sinusitis, upper respiratory tract infection, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Bacterial infection, herpes simplex infection, hypersensitivity, influenza, tonsillitis, viral infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening): Anaphylaxis, angioneurotic edema, eczema herpeticum, facial edema, flushing (ethanol-associated), lymphadenopathy, ocular irritation (following application near eyes), malignancy (basal cell carcinoma, squamous cell carcinoma, malignant melanoma, lymphoma), skin discoloration",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pimecrolimus or any component; Netherton's syndrome due to potential for increased systemic absorption; application to site with active cutaneous viral infection (treat and clear infection prior to the start of therapy); application on malignant or premalignant skin conditions",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1049360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in immunocompromised patients and in patients who have experienced adverse effects to topical cyclosporine or tacrolimus.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1049359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pimecrolimus therapy may be associated with an increased risk for eczema herpeticum, varicella zoster, or herpes simplex virus infection; consider discontinuing therapy in patients who develop lymphadenopathy or in patients who have skin papillomas which worsen. Cream contains benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F209941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F209912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: Pimecrolimus may enhance the adverse/toxic effect of Immunosuppressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F209914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F209924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no adequate and well-controlled studies in pregnant women; use only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1049367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Check skin for signs of worsening condition (increase in pruritus, erythema, excoriation, and lichenification)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds with high affinity to macrophilin-12 (FKBP-12) inhibiting the calcium-dependent phosphatase activity of calcineurin. Inhibits T-cell activation by blocking the transcription and synthesis in human T-cells of early cytokines interleukin-2, interferon gamma (T",
"     <sub>",
"      h",
"     </sub>",
"     1-type), interleukin-4, and interleukin-10 (T",
"     <sub>",
"      h",
"     </sub>",
"     2-type). Prevents the release of inflammatory cytokines and mediators from mast cells after stimulation by antigen/IgE.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1049373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Time to significant improvement: 8 days",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1049374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Topical: Low systemic absorption; blood concentration of pimecrolimus was routinely &lt;2 ng/mL with treatment of atopic dermatitis in adult patients (13% to 62% BSA involvement); blood concentration of pimecrolimus was &lt;3 ng/mL in 26 pediatric patients 2-14 years of age with atopic dermatitis (20% to 69% BSA involvement). Detectable blood levels were observed in a higher proportion of children as compared to adults and may be due to the larger surface area to body mass ratio seen in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99.5%, primarily to various lipoproteins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver by the cytochrome P450 3A4 system",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Terminal: 30-40 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Topical: 2-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 80% in the feces as metabolites",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1049366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/7/3189?source=see_link\">",
"      see \"Pimecrolimus: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if any signs of serious infection occurs or if symptoms of atopic dermatitis do not improve within 6 weeks",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Eichenfield LF, Lucky AW, Boguniewicz M, et al, &ldquo;Safety and Efficacy of Pimecrolimus (ASM 981) Cream 1% in the Treatment of Mild and Moderate Atopic Dermatitis in Children and Adolescents,&rdquo;",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 2002, 46(4):495-504.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18612/abstract-text/11907497/pubmed\" id=\"11907497\" target=\"_blank\">",
"        11907497",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wahn U, Bos JD, Goodfield M, et al, &ldquo;Efficacy and Safety of Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2002, 110(1 Pt 1):e2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18612/abstract-text/12093983 /pubmed\" id=\"12093983 \" target=\"_blank\">",
"        12093983",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wellington K and Jarvis B, &ldquo;Topical Pimecrolimus: A Review of Its Clinical Potential in the Management of Atopic Dermatitis,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2002, 62(5):817-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18612/abstract-text/11929333/pubmed\" id=\"11929333\" target=\"_blank\">",
"        11929333",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12706 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-869C284B9E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_11_18612=[""].join("\n");
var outline_f18_11_18612=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709211\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209930\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209931\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049368\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049361\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209917\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209905\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874783\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049371\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049364\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049370\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7898347\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209951\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049375\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049360\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049359\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209941\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209912\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209914\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209924\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049367\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049358\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049373\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049374\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049366\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12706\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12706|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=related_link\">",
"      Pimecrolimus: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/7/3189?source=related_link\">",
"      Pimecrolimus: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_11_18613="Pentazocine and acetaminophen: Patient drug information";
var content_f18_11_18613=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pentazocine and acetaminophen: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/42/37542?source=see_link\">",
"     see \"Pentazocine and acetaminophen: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F13132643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3491790",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Acetaminophen may cause very bad liver problems. Your risk is higher if you take more than 4 grams of acetaminophen a day, drink beer, wine, or mixed drinks, or have liver disease. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pentazocine, acetaminophen, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfite allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701044",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink beer, wine, or mixed drinks or take any drugs that have alcohol.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703781",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696680",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid other sources of acetaminophen. An overdose may cause problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697135",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a history of a drug or drinking problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful if you have G6PD deficiency. Anemia may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697223",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have GI (gastrointestinal) disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699000",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Poor pain control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3927405",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug with other strong pain drugs or if you are using a pain patch without talking to your doctor first.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take by mouth only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694768",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take more than what your doctor told you to take. Liver problems may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a pain diary.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11226 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-197.136.42.3-AA8FF843F1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_11_18613=[""].join("\n");
var outline_f18_11_18613=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13132643\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025743\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025742\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025747\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025748\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025750\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025745\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025746\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025751\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025752\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/42/37542?source=related_link\">",
"      Pentazocine and acetaminophen: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_11_18614="Treatment of specific hypertensive emergencies";
var content_f18_11_18614=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of specific hypertensive emergencies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/11/18614/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/11/18614/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/11/18614/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/11/18614/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/11/18614/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/11/18614/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/11/18614/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with significantly elevated blood pressure (diastolic pressure &ge;120 mmHg), have no acute, end-organ injury. Although some propose relatively rapid antihypertensive therapy in this setting, there may be more risk than benefit from such an aggressive regimen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28246?source=see_link\">",
"     \"Management of severe asymptomatic hypertension (hypertensive urgencies)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are, however, hypertensive emergencies in which rapid lowering of the BP is indicated. These disorders will be reviewed here with the exception of malignant hypertension and hypertensive encephalopathy, which are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=see_link\">",
"     \"Malignant hypertension and hypertensive encephalopathy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANTIHYPERTENSIVE DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An overview of the mechanism of action, doses, and routes of administration of the antihypertensive drugs that may be used in this setting is provided in the following table (",
"    <a class=\"graphic graphic_table graphicRef64066 graphicRef75865 \" href=\"UTD.htm?39/49/40733\">",
"     table 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18614/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    or other potent diuretics are often needed to enhance the efficacy of these agents.",
"   </p>",
"   <p>",
"    The usual dose of the different drugs will be briefly summarized here. A more detailed discussion, including side effects, is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18853?source=see_link\">",
"     \"Drug treatment of hypertensive emergencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"       Nitroprusside",
"      </a>",
"      <strong>",
"      </strong>",
"      &mdash; a rapidly acting arteriolar and venous dilator, given as an intravenous infusion. Initial dose: 0.25 to 0.5",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per min; maximum dose: 8 to 10",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per min which should be continued for no more than 10 minutes.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       Nitroglycerin",
"      </a>",
"      &mdash; a rapidly acting venous and, to a lesser degree, arteriolar dilator, given as an intravenous infusion. Initial dose: 5",
"      <span class=\"nowrap\">",
"       mcg/min;",
"      </span>",
"      maximum dose: 100",
"      <span class=\"nowrap\">",
"       mcg/min.",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"       Labetalol",
"      </a>",
"      <strong>",
"      </strong>",
"      &mdash; an alpha- and &szlig;-adrenergic blocker, given as an intravenous bolus or infusion. Bolus: 20 mg initially, followed by 20 to 80 mg every 10 minutes to a total dose of 300 mg. Infusion: 0.5 to 2",
"      <span class=\"nowrap\">",
"       mg/min.",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"       Nicardipine",
"      </a>",
"      <strong>",
"      </strong>",
"      &mdash; a calcium channel blocker, given as an intravenous infusion. Initial dose: 5",
"      <span class=\"nowrap\">",
"       mg/h;",
"      </span>",
"      maximum dose: 15",
"      <span class=\"nowrap\">",
"       mg/h.",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/25/39317?source=see_link\">",
"       Clevidipine",
"      </a>",
"      <strong>",
"      </strong>",
"      &mdash; a calcium channel blocker. Initial dose: 1",
"      <span class=\"nowrap\">",
"       mg/hour;",
"      </span>",
"      maximum dose: 16",
"      <span class=\"nowrap\">",
"       mg/hour.",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35284?source=see_link\">",
"       Fenoldopam",
"      </a>",
"      <strong>",
"      </strong>",
"      &mdash; a peripheral dopamine-1 receptor agonist, given as an intravenous infusion. Initial dose: 0.1",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per min; the dose is titrated at 15 min intervals, depending upon the blood pressure response.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       Hydralazine",
"      </a>",
"      <strong>",
"      </strong>",
"      &mdash; an arteriolar dilator, given as an intravenous bolus. Initial dose: 10 mg given every 20 to 30 minutes; maximum dose: 20 mg.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       Propranolol",
"      </a>",
"      <strong>",
"      </strong>",
"      &mdash; a &szlig;-adrenergic blocker, given as an intravenous infusion and then followed by oral therapy. Dose: 1 to 10 mg load, followed by 3",
"      <span class=\"nowrap\">",
"       mg/h.",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34485?source=see_link\">",
"       Phentolamine",
"      </a>",
"      <strong>",
"      </strong>",
"      &mdash; an alpha-adrenergic blocker, given as an intravenous bolus. Dose: 5 to 10 mg every 5 to 15 minutes.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/22/20839?source=see_link\">",
"       Enalaprilat",
"      </a>",
"      &mdash; an angiotensin converting enzyme inhibitor, given as an intravenous bolus. Dose: 1.25 mg every six hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1240652\">",
"    <span class=\"h2\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    is most rapid and potent. It acts within seconds and has a duration of action of only 2 to 5 minutes. Thus, hypotension can be easily reversed by temporarily discontinuing the infusion. Nitroprusside is generally considered to be the most effective parenteral drug for most hypertensive emergencies. The major limitation to the use of this drug is the development of cyanide toxicity in patients treated with high doses, for a prolonged period (&gt;24 to 48 hours), or with underlying renal insufficiency.",
"   </p>",
"   <p>",
"    Alternatives to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    include intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"     nicardipine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35284?source=see_link\">",
"     fenoldopam",
"    </a>",
"    ; hypotension is uncommon with these drugs and cyanide toxicity is not an issue.",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35284?source=see_link\">",
"     fenoldopam",
"    </a>",
"    , a dopamine agonist that acts at the vasodilator DA1 receptors, is as effective and almost as short-acting as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18614/abstract/3\">",
"     3",
"    </a>",
"    ]; however, it has the advantages of increasing renal blood flow and sodium excretion, of not being associated with the accumulation of toxic metabolites, and of not requiring shielding from light.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal therapy, including the choice of agent and the blood pressure goal, varies according to the specific hypertensive emergency [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18614/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49218673\">",
"    <span class=\"h2\">",
"     Malignant hypertension and hypertensive encephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A modest reduction of the BP, by no more than 25 percent of the initial value within the first 24 hours, with a parenteral vasodilator (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    ) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    is the initial strategy for management of malignant hypertension and hypertensive encephalopathy. These issues are discussed elsewhere in more detail. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=see_link\">",
"     \"Malignant hypertension and hypertensive encephalopathy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Ischemic stroke or subarachnoid or intracerebral hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of reducing the BP in these disorders must be weighed against possible worsening of cerebral ischemia induced by the thrombotic lesion or by cerebral vasospasm. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17305?source=see_link\">",
"     \"Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32650?source=see_link&amp;anchor=H18#H18\">",
"     \"Spontaneous intracerebral hemorrhage: Prognosis and treatment\", section on 'Blood pressure control'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\", section on 'Intracranial pressure and blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These cerebrovascular events are characterized by the abrupt onset of usually focal neurologic findings. This is in contrast to the typically insidious onset of headache, nausea, vomiting, and confusion seen in hypertensive encephalopathy, a disorder in which rapid lowering of the BP generally leads to resolution of the symptoms within 24 to 48 hours. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=see_link\">",
"     \"Malignant hypertension and hypertensive encephalopathy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Acute pulmonary edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension in patients with acute left ventricular failure due to systolic dysfunction should be principally treated with vasodilators.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     Nitroprusside",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    with a loop diuretic is the regimen of choice for this problem. Drugs that increase cardiac work (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    ) or decrease cardiac contractility (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    or other beta blocker) should be avoided. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: General considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Angina pectoris or acute myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute coronary insufficiency frequently increases the systemic blood pressure. Beta adrenergic blockers should be administered to all patients without contraindications who experience a myocardial infarction.",
"   </p>",
"   <p>",
"    Intravenous parenteral vasodilators, principally",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    , are effective and may reduce mortality in patients with acute myocardial infarction, with or without hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18614/abstract/4\">",
"     4",
"    </a>",
"    ]. Drugs that increase cardiac work (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    ) are contraindicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Aortic dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;With acute aortic dissection, the stresses that damage the vessel wall are related to the mean pressure, the width of the pulse pressure, and the maximal rate of rise of the pressure",
"    <span class=\"nowrap\">",
"     (dp/dt).",
"    </span>",
"    Drugs that diminish",
"    <span class=\"nowrap\">",
"     dp/dt",
"    </span>",
"    are the optimal agents to treat a dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18614/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with aortic dissection, an intravenous beta adrenergic blocker should be given to reduce the heart rate below 60",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    and maintain the systolic blood pressure between 100 to 120 mmHg or the lowest level that is tolerated.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     Nitroprusside",
"    </a>",
"    can be added to further control blood pressure but should",
"    <strong>",
"     not",
"    </strong>",
"    &nbsp;be given without first controlling the heart rate with beta blockade.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Withdrawal of antihypertensive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abrupt discontinuation of a short-acting sympathetic blocker (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    ) can lead to severe hypertension and coronary ischemia due to upregulation of sympathetic receptors. Control of the BP can be achieved in this setting by readministration of the discontinued drug and, if necessary,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34485?source=see_link\">",
"     phentolamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1827?source=see_link\">",
"     \"Withdrawal syndromes with antihypertensive therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Acute increase in sympathetic activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to drug withdrawal, increased adrenergic activity can lead to severe hypertension in a variety of other clinical settings. These include: (1) pheochromocytoma; (2) autonomic dysfunction, as in the Guillain-Barr&eacute; syndrome or post-spinal cord injury; and (3) the use of sympathomimetic drugs, such as phenylpropanolamine, cocaine, amphetamines, phencyclidine, or the combination of an MAO (monoamine oxidase) inhibitor and the ingestion of tyramine-containing foods (such as most fermented cheeses, smoked or aged meats, Chianti, champagne, and avocados) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18614/abstract/2\">",
"     2",
"    </a>",
"    ]. The rise in BP seen in the last setting is due to an MAO inhibitor-induced decline in intestinal tyramine metabolism, followed by increased tyramine absorption and a subsequent tyramine-induced release of endogenous catecholamines. A more complete list of possibly dangerous foods can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Control of the hypertension in these disorders can be achieved with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34485?source=see_link\">",
"     phentolamine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    . Administration of a beta blocker alone is contraindicated, since inhibition of beta-receptor-induced vasodilation results in unopposed alpha-adrenergic vasoconstriction and a further rise in BP [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18614/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    have been widely used in pregnant women with severe hypertension, which is usually due to preeclampsia or exacerbation of preexistent hypertension. These issues as well as antihypertensive drugs that may be contraindicated in pregnancy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link&amp;anchor=H8#H8\">",
"     \"Management of hypertension in pregnant and postpartum women\", section on 'Acute therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics links (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/57/27539?source=see_link\">",
"       \"Patient information: High blood pressure emergencies (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23657850\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypertensive emergencies require rapid lowering of the blood pressure (BP). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of antihypertensive drugs can be used to treat hypertensive emergencies; an overview of the mechanism of action, doses, and routes of administration of these agents is provided in the following table (",
"      <a class=\"graphic graphic_table graphicRef64066 graphicRef75865 \" href=\"UTD.htm?39/49/40733\">",
"       table 1A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Antihypertensive drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Malignant hypertension and hypertensive encephalopathy can be managed with various parenteral antihypertensive medications, most commonly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"       nicardipine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"       labetalol",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35284?source=see_link\">",
"       fenoldopam",
"      </a>",
"      . The blood pressure should not be lowered by more than 25 percent of the original value. (See",
"      <a class=\"local\" href=\"#H49218673\">",
"       'Malignant hypertension and hypertensive encephalopathy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=see_link\">",
"       \"Malignant hypertension and hypertensive encephalopathy in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The optimal antihypertensive regimen, rapidity of blood pressure lowering, and blood pressure goal varies in patients with severe hypertension who have an ischemic stroke or subarachnoid or intracerebral hemorrhage. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Ischemic stroke or subarachnoid or intracerebral hemorrhage'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17305?source=see_link\">",
"       \"Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32650?source=see_link&amp;anchor=H18#H18\">",
"       \"Spontaneous intracerebral hemorrhage: Prognosis and treatment\", section on 'Blood pressure control'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=see_link&amp;anchor=H6#H6\">",
"       \"Treatment of aneurysmal subarachnoid hemorrhage\", section on 'Intracranial pressure and blood pressure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Severe hypertension in patients with acute left ventricular failure due to systolic dysfunction should be principally treated with vasodilators (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      or nitroglycerine). Drugs that increase cardiac work (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      ) or decrease cardiac contractility (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"       labetalol",
"      </a>",
"      or other beta blocker) should be avoided. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Acute pulmonary edema'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=see_link\">",
"       \"Treatment of acute decompensated heart failure: General considerations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute coronary insufficiency frequently increases the systemic blood pressure. Beta adrenergic blockers should be administered to all patients without contraindications who experience a myocardial infarction. Intravenous parenteral vasodilators, principally",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      <strong>",
"       ,",
"      </strong>",
"      effectively lower blood pressure and reduce symptoms in patients with acute myocardial infarction. Drugs that increase cardiac work (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      ) are contraindicated. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Angina pectoris or acute myocardial infarction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"       \"Overview of the acute management of ST elevation myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"       \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with aortic dissection, an intravenous beta adrenergic blocker should be given to reduce the heart rate below 60",
"      <span class=\"nowrap\">",
"       beats/min",
"      </span>",
"      and maintain the systolic blood pressure between 100 to 120 mmHg or the lowest level that is tolerated.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"       Nitroprusside",
"      </a>",
"      can be added to further control blood pressure but should",
"      <strong>",
"       not",
"      </strong>",
"      &nbsp;be given without first controlling the heart rate with beta blockade. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Aortic dissection'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25449?source=see_link&amp;anchor=H3#H3\">",
"       \"Management of aortic dissection\", section on 'Acute management'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18614/abstract/1\">",
"      Rosei EA, Salvetti M, Farsang C. European Society of Hypertension Scientific Newsletter: treatment of hypertensive urgencies and emergencies. J Hypertens 2006; 24:2482.",
"     </a>",
"    </li>",
"    <li>",
"     Kaplan NM, Victor RG. Chapter 8: Hypertensive Crises. In: Kaplan's Clinical Hypertension, 10th Ed, Lippincott, Williams &amp; Wilkins, Philadelphia 2010. p.274.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18614/abstract/3\">",
"      Murphy MB, Murray C, Shorten GD. Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med 2001; 345:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18614/abstract/4\">",
"      Lau J, Antman EM, Jimenez-Silva J, et al. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992; 327:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18614/abstract/5\">",
"      Pr&ecirc;tre R, Von Segesser LK. Aortic dissection. Lancet 1997; 349:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18614/abstract/6\">",
"      Prichard BN, Ross EJ. Use of propranolol in conjunction with alpha receptor blocking drugs in pheochromocytoma. Am J Cardiol 1966; 18:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18614/abstract/7\">",
"      Brown H, Goldberg PA, Selter JG, et al. Hemorrhagic pheochromocytoma associated with systemic corticosteroid therapy and presenting as myocardial infarction with severe hypertension. J Clin Endocrinol Metab 2005; 90:563.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3837 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-CF9877BBA9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_11_18614=[""].join("\n");
var outline_f18_11_18614=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23657850\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANTIHYPERTENSIVE DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1240652\">",
"      Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49218673\">",
"      Malignant hypertension and hypertensive encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Ischemic stroke or subarachnoid or intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Acute pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Angina pectoris or acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Withdrawal of antihypertensive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Acute increase in sympathetic activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23657850\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3837\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3837|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/2/2093\" title=\"table 1A\">",
"      Drugs for HTV emergencies A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/53/10076\" title=\"table 1B\">",
"      Drugs for HTV emergencies B",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17305?source=related_link\">",
"      Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=related_link\">",
"      Clinical presentation and diagnosis of pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18853?source=related_link\">",
"      Drug treatment of hypertensive emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=related_link\">",
"      Malignant hypertension and hypertensive encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25449?source=related_link\">",
"      Management of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28246?source=related_link\">",
"      Management of severe asymptomatic hypertension (hypertensive urgencies)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/57/27539?source=related_link\">",
"      Patient information: High blood pressure emergencies (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32650?source=related_link\">",
"      Spontaneous intracerebral hemorrhage: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=related_link\">",
"      Treatment of acute decompensated heart failure: General considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=related_link\">",
"      Treatment of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1827?source=related_link\">",
"      Withdrawal syndromes with antihypertensive therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_11_18615="Ropinirole: Drug information";
var content_f18_11_18615=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ropinirole: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?19/46/20196?source=see_link\">",
"    see \"Ropinirole: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F219144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Requip&reg;;",
"     </li>",
"     <li>",
"      Requip&reg; XL&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F219145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      CO Ropinirole;",
"     </li>",
"     <li>",
"      JAMP-Ropinirole;",
"     </li>",
"     <li>",
"      PMS-Ropinirole;",
"     </li>",
"     <li>",
"      RAN&trade;-Ropinirole;",
"     </li>",
"     <li>",
"      Requip&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F219173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anti-Parkinson's Agent, Dopamine Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F219148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Parkinson's disease:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Immediate release tablet: The dosage should be increased to achieve a maximum therapeutic effect, balanced against the principal side effects of nausea, dizziness, somnolence and dyskinesia. Recommended starting dose is 0.25 mg 3 times/day; based on individual patient response, the dosage should be titrated with weekly increments as described below:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &bull; Week 1: 0.25 mg 3 times/day; total daily dose: 0.75 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     &bull; Week 2: 0.5 mg 3 times/day; total daily dose: 1.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     &bull; Week 3: 0.75 mg 3 times/day; total daily dose: 2.25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     &bull; Week 4: 1 mg 3 times/day; total daily dose: 3 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     After week 4, if necessary, daily dosage may be increased by 1.5 mg/day on a weekly basis up to a dose of 9 mg/day, and then by up to 3 mg/day weekly to a total of 24 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Parkinson's disease discontinuation taper:",
"     </i>",
"     Ropinirole should be gradually tapered over 7 days as follows: reduce frequency of administration from 3 times daily to twice daily for 4 days, then reduce to once daily for remaining 3 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Extended release tablet: Initial: 2 mg once daily for 1-2 weeks, followed by increases of 2 mg/day at weekly or longer intervals based on therapeutic response and tolerability (maximum: 24 mg/day);",
"     <b>",
"      Note:",
"     </b>",
"     When discontinuing gradually taper over 7 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Restless legs syndrome:",
"     </b>",
"     Oral: Immediate release tablets: Initial: 0.25 mg once daily 1-3 hours before bedtime. Dose may be increased after 2 days to 0.5 mg daily, and after 7 days to 1 mg daily. Dose may be further titrated upward in 0.5 mg increments every week until reaching a daily dose of 3 mg during week 6. If symptoms persist or reappear, the daily dose may be increased to a maximum of 4 mg beginning week 7.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses up to 4 mg per day may be discontinued without tapering.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Converting from ropinirole immediate release tablets to ropinirole extended-release tablets:",
"     </b>",
"     Choose a once daily extended-release dose that most closely matches current immediate-release daily dose.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F219149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clearance is reduced; however, no dosage adjustment necessary. Titrate dose to clinical response. Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F219150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Moderate renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute): No adjustment needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute): Use with caution; has not been studied in this patient population.",
"     <b>",
"      Note:",
"     </b>",
"     The Canadian labeling recommends to avoid use in patients with severe renal impairment and who are not undergoing regular hemodialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Hemodialysis: Canadian labeling (not in U.S. labeling): Initial: 0.25 mg 3 times daily; may titrate dose upward based on tolerability and efficacy (maximum dose: 18 mg/day); postdialysis supplemental doses are not required",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F6158751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Titrate with caution; has not been studied.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F219124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Requip&reg;: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 2 mg, 4 mg, 6 mg, 8 mg, 12 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Requip&reg; XL&trade;: 2 mg, 4 mg, 6 mg, 8 mg, 12 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F219111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6158752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals; taking with food may reduce nausea. Swallow extended-release tablet whole; do not crush, split, or chew.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F219125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of idiopathic Parkinson's disease; in patients with early Parkinson's disease who were not receiving concomitant levodopa therapy as well as in patients with advanced disease on concomitant levodopa; treatment of moderate-to-severe primary Restless Legs Syndrome (RLS)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F219181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Requip&reg; may be confused with Reglan&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       ROPINIRole may be confused with RisperDAL&reg;, risperiDONE, ropivacaine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F219171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Data inclusive of trials in early Parkinson's disease (without levodopa) and Restless Legs Syndrome:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Syncope (1% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Somnolence (11% to 40%), dizziness (6% to 40%), fatigue (8% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (immediate release: 40% to 60%; extended release: 19%), vomiting (11% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Viral infection (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Dependent/leg edema (2% to 7%), orthostasis (1% to 6%), hypertension (5%), chest pain (4%), flushing (3%), palpitation (3%), peripheral ischemia (2% to 3%), atrial fibrillation (2%), extrasystoles (2%), hypotension (2%), tachycardia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Pain (3% to 8%), headache (extended release: 6%), confusion (5%), hallucinations (up to 5%; dose related), hypoesthesia (4%), amnesia (3%), malaise (3%), yawning (3%), concentration impaired (2%), vertigo (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Hyperhidrosis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (4% to 10%), abdominal pain (3% to 7%), constipation (&ge;5%), xerostomia (3% to 5%), diarrhea (5%), anorexia (4%), flatulence (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (5%), impotence (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (6%), arthralgia (4%), muscle cramps (3%), paresthesia (3%), hyperkinesia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Abnormal vision (6%), xerophthalmia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (6% to 9%), rhinitis (4%), sinusitis (4%), bronchitis (3%), dyspnea (3%), influenza (3%), cough (3%), nasal congestion (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis increased (3% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Advanced Parkinson's disease (with levodopa):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (immediate release: 26%; extended-release: 8%), somnolence (immediate release: 20%, extended release: 7%), headache (17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (immediate release: 30%; extended-release: 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Dyskinesias (immediate release: 34%; extended-release: 13%; dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (2% to 5%; including orthostatic), peripheral edema (4%), syncope (3%), hypertension (3%; dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Hallucinations (7% to 10%; dose related), confusion (9%), anxiety (2% to 6%), amnesia (5%), nervousness (5%), pain (5%), vertigo (4%), abnormal dreaming (3%), paresis (3%), aggravated parkinsonism, insomnia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (6% to 9%), vomiting (7%), constipation (4% to 6%), diarrhea (3% to 5%), xerostomia (2% to 5%), dysphagia (2%), flatulence (2%), salivation increased (2%), weight loss (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (6%), pyuria (2%), urinary incontinence (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Falls (2% to 10%; dose related), arthralgia (7%), tremor (6%), hypokinesia (5%), paresthesia (5%), arthritis (3%), back pain (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Diplopia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract infection (9%), dyspnea (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Injury, diaphoresis increased (7%), viral infection, increased drug level (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Other adverse effects (all phase 2/3 trials for Parkinson&rsquo;s disease and Restless Leg Syndrome):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &ge;1%: Asthma, BUN increased, depression, gastroenteritis, gastrointestinal reflux, irritability, migraine, muscle spasm, myalgia, neck pain, neuralgia, osteoarthritis, pharyngolaryngeal pain, rash, rigors, sleep disorder, tendonitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal coordination, acidosis, agitation, aneurysm, angina, aphasia, behavioral disorders, bradycardia, bundle branch block, cardiac arrest, cardiac failure, cardiac valvulopathy, cardiomegaly, cellulitis, cholecystitis, cholelithiasis, choreoathetosis, colitis, coma, conjunctival hemorrhage, dehydration, delusion, delirium, diabetes mellitus, diverticulitis, Dupuytren&rsquo;s contracture, dysphonia, electrolyte disturbances, eosinophilia, extrapyramidal symptoms, gangrene, gastrointestinal hemorrhage, gastrointestinal ulceration, glaucoma, goiter, gynecomastia, hematuria, hemiparesis, hemiplegia, hepatitis (ischemic), hyperbilirubinemia, hypercholesterolemia,  hyper-/hypothyroidism, hyper-/hypotonia, hypoglycemia, hyponatremia, hyperphosphatemia, hypersensitivity reactions (angioedema, pruritus), hyperuricemia, impulsive/compulsive behaviors (eg, pathological gambling, hypersexuality, binge eating), infections (bacterial, viral, or fungal); interstitial lung disease, intestinal obstruction, leukocytosis, leukopenia, limb embolism, liver enzymes increased, lymphadenopathy, lymphedema, lymphocytosis, lymphopenia, menstrual abnormalities, mitral insufficiency, MI, neoplasms (various), pancreatitis, paralysis, paranoia, peripheral neuropathy, photosensitivity, pleural effusion, pleural fibrosis, proteinuria, psychiatric disorders, pulmonary edema, pulmonary embolism, renal calculus, renal failure (acute), seizure, sepsis, SIADH, skin disorders, stomatitis, stupor, subarachnoid hemorrhage, suicide attempt, SVT, thrombocytopenia, thrombosis, tinnitus, tongue edema, torticollis, urticaria, vagina/uterine hemorrhage, ventricular tachycardia, visual disturbances",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F219129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ropinirole or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F219115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hallucinations: May cause hallucinations (dose dependent); risk may be increased in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Impulse control disorders: Dopamine agonists used for Parkinson&rsquo;s disease or restless legs syndrome have been associated with compulsive behaviors and/or loss of impulse control, which has manifested as pathological gambling, libido increases (hypersexuality), and/or binge eating. Causality has not been established, and controversy exists as to whether this phenomenon is related to the underlying disease, prior behaviors/addictions and/or drug therapy. Dose reduction or discontinuation of therapy has been reported to reverse these behaviors in some, but not all cases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Melanoma: Risk for melanoma development is increased in Parkinson&rsquo;s disease patients; drug causation or factors contributing to risk have not been established. Patients should be monitored closely and periodic skin examinations should be performed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension; Parkinson's disease patients appear to have an impaired capacity to respond to a postural challenge. Use with caution in patients at risk of hypotension (such as those receiving antihypertensive or antiarrhythmic drugs) or where transient hypotensive episodes would be poorly tolerated (cardiovascular disease or cerebrovascular disease). Parkinson's patients being treated with dopaminergic agonists ordinarily require careful monitoring for signs and symptoms of postural hypotension, especially during dose escalation, and should be informed of this risk. Syncope, sometimes associated with bradycardia, was observed in association with ropinirole in both early Parkinson's disease (without levodopa) patients and advanced Parkinson's disease (with levodopa) patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pleural/retroperitoneal fibrosis: Risk of fibrotic complications (eg, pleural effusion/fibrosis, interstitial lung disease) has been reported in patients receiving ropinirole; drug causation has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Retinal changes: Pathologic degenerative changes were observed in the retinas of albino rats during studies with this agent, but were not observed in the retinas of albino mice or in other species. The significance of these data for humans remains uncertain.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Somnolence: Patients have reported falling asleep while engaging in activities of daily living; this has been reported to occur without significant warning signs. Monitor for daytime somnolence or pre-existing sleep disorder; caution with concomitant sedating medication; discontinue if significant daytime sleepiness or episodes of falling asleep occur. Patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Use with caution in patients receiving other CNS depressants or psychoactive agents. Effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dyskinesias: Use with caution in patients with pre-existing dyskinesias; may be exacerbated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use in hepatic impairment has not been studied; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychotic disorders: Avoid use in patients with a major psychotic disorder; may exacerbate psychosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use in severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute) has not been studied; use with caution.",
"     <b>",
"      Note:",
"     </b>",
"     The Canadian labeling recommends to avoid use in patients with severe renal impairment and who are not undergoing regular hemodialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Restless legs syndrome (RLS): Augmentation (earlier onset of symptoms in the evening/afternoon, increase and/or spread of symptoms to other extremities) or rebound (shifting of symptoms to early morning hours) may occur in some RLS patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Dopaminergic agents have been associated with a syndrome resembling neuroleptic malignant syndrome on abrupt withdrawal or significant dosage reduction after long-term use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F219167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F219120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics (Atypical): May diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist). Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson's disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics (Typical): Anti-Parkinson's Agents (Dopamine Agonist) may diminish the therapeutic effect of Antipsychotics (Typical). Antipsychotics (Typical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).  Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson's agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ciprofloxacin (Systemic): May decrease the metabolism of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May increase the serum concentration of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the adverse/toxic effect of Anti-Parkinson's Agents (Dopamine Agonist).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F219142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid kava kava, gotu kola, valerian, St John's wort (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F219121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6158625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in animal studies. There are no adequate and well-controlled studies in pregnant women; use only if potential benefit outweighs the risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F219152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6158627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ropinirole inhibits prolactin secretion in humans and may potentially inhibit lactation. It is not known if ropinirole is excreted into breast milk. Due to the potential for serious adverse reactions, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F219133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals; taking with food may reduce nausea.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F219132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Requip XL Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (30): $91.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (30): $182.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg (30): $273.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg (30): $273.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12 mg (30): $456.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (ROPINIRole HCl ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (30): $82.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (30): $164.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg (30): $246.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg (30): $246.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12 mg (30): $410.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Requip Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg (100): $375.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (100): $375.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $375.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $375.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg (100): $388.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (100): $388.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $388.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (ROPINIRole HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg (100): $250.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (100): $250.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $250.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $250.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg (100): $259.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (100): $259.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $259.85",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F639157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Blood pressure (orthostatic); daytime alertness",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F219134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adartrel (CH, FR, GB, IE, NO, SE);",
"     </li>",
"     <li>",
"      Appese (AU);",
"     </li>",
"     <li>",
"      Dopapro (KP);",
"     </li>",
"     <li>",
"      Loquip (KP);",
"     </li>",
"     <li>",
"      Newquip (KP);",
"     </li>",
"     <li>",
"      Pakinol (KP);",
"     </li>",
"     <li>",
"      Parkirop (IN);",
"     </li>",
"     <li>",
"      Parokin (KP);",
"     </li>",
"     <li>",
"      Repreve (AU, NZ);",
"     </li>",
"     <li>",
"      Requip (AR, AT, BE, BG, BR, CH, CN, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, HR, HU, IE, IL, IT, KP, MY, NL, NO, NZ, PK, PL, PT, SE, SG, TR, TW);",
"     </li>",
"     <li>",
"      Requip PD (HK, ID, MY, PH, SG, TH, TW);",
"     </li>",
"     <li>",
"      Ropimax (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F219114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ropinirole has a high relative",
"     <i>",
"      in vitro",
"     </i>",
"     specificity and full intrinsic activity at the D",
"     <sub>",
"      2",
"     </sub>",
"     and D",
"     <sub>",
"      3",
"     </sub>",
"     dopamine receptor subtypes, binding with higher affinity to D",
"     <sub>",
"      3",
"     </sub>",
"     than to D",
"     <sub>",
"      2",
"     </sub>",
"     or D",
"     <sub>",
"      4",
"     </sub>",
"     receptor subtypes; relevance of D",
"     <sub>",
"      3",
"     </sub>",
"     receptor binding in Parkinson's disease is unknown. Ropinirole has moderate",
"     <i>",
"      in vitro",
"     </i>",
"     affinity for opioid receptors. Ropinirole and its metabolites have negligible",
"     <i>",
"      in vitro",
"     </i>",
"     affinity for dopamine D",
"     <sub>",
"      1",
"     </sub>",
"     , 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     , 5-HT",
"     <sub>",
"      2",
"     </sub>",
"     , benzodiazepine, GABA, muscarinic, alpha",
"     <sub>",
"      1",
"     </sub>",
"     -, alpha",
"     <sub>",
"      2",
"     </sub>",
"     -, and beta-adrenoreceptors. Although precise mechanism of action of ropinirole is unknown, it is believed to be due to stimulation of postsynaptic dopamine D",
"     <sub>",
"      2",
"     </sub>",
"     -type receptors within the caudate putamen in the brain. Ropinirole caused decreases in systolic and diastolic blood pressure at doses &gt;0.25 mg. The mechanism of ropinirole-induced postural hypotension is believed to be due to D",
"     <sub>",
"      2",
"     </sub>",
"     -mediated blunting of the noradrenergic response to standing and subsequent decrease in peripheral vascular resistance.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F219128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Not affected by food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 525 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic via CYP1A2 to inactive metabolites; first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Absolute: 45% to 55%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Immediate release: ~1-2 hours; Extended release: 6-10 hours; T",
"     <sub>",
"      max",
"     </sub>",
"     increased by 2.5-3 hours when drug taken with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&lt;10% as unchanged drug, 60% as metabolites)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Reduced by 15% to 30% in patients &gt;65 years of age",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Factor SA, &ldquo;Current Status of Symptomatic Medical Therapy in Parkinson&rsquo;s Disease,&rdquo;",
"      <i>",
"       Neurotherapeutics",
"      </i>",
"      , 2008, 5(2):164-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18615/abstract-text/18394561/pubmed\" id=\"18394561\" target=\"_blank\">",
"        18394561",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Happe S, Sauter C, Klosch G, et al, &ldquo;Gabapentin Versus Ropinirole in the Treatment of Idiopathic Restless Legs Syndrome,&rdquo;",
"      <i>",
"       Neuropsychobiology",
"      </i>",
"      , 2003, 48(2):82-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18615/abstract-text/14504416/pubmed\" id=\"14504416\" target=\"_blank\">",
"        14504416",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Molina JA, S&agrave;inz-Artiga MJ, Fraile A, et al, &ldquo;Pathologic Gambling in Parkinson's Disease: A Behavioral Manifestation of Pharmacologic Treatment,&rdquo;",
"      <i>",
"       Mov Disord",
"      </i>",
"      , 2000, 15(5):869-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18615/abstract-text/11009192/pubmed\" id=\"11009192\" target=\"_blank\">",
"        11009192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olanow CW, Watts RL, and Koller WC, &ldquo;An Algorithm (Decision Tree) for the Management of Parkinson's Disease (2001): Treatment Guidelines,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2001, 56(11 Suppl 5):1-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18615/abstract-text/11402154/pubmed\" id=\"11402154\" target=\"_blank\">",
"        11402154",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saletu M, Anderer P, Saletu-Zyhlarz GM, et al, &ldquo;Comparative Placebo-Controlled Polysomnographic and Psychometric Studies on the Acute Effects of Gabapentin Versus Ropinirole in Restless Legs Syndrome,&rdquo;",
"      <i>",
"       J Neural Transm",
"      </i>",
"      , 2010, 117(4):463-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18615/abstract-text/20049491/pubmed\" id=\"20049491\" target=\"_blank\">",
"        20049491",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stern MB, &ldquo;Contemporary Approaches to the Pharmacotherapeutic Management of Parkinson's Disease: An Overview,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1997, 49(1 Suppl 1):2-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18615/abstract-text/9222162/pubmed\" id=\"9222162\" target=\"_blank\">",
"        9222162",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Watts RL, &ldquo;The Role of Dopamine Agonists in Early Parkinson's Disease,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1997, 49(1 Suppl 1):34-48.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18615/abstract-text/9222273/pubmed\" id=\"9222273\" target=\"_blank\">",
"        9222273",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weintraub D, Siderowf AD, Potenza MN, et al, &ldquo;Association of Dopamine Agonist Use With Impulse Control Disorders in Parkinson Disease,&rdquo;",
"      <i>",
"       Arch Neurol",
"      </i>",
"      , 2006, 63(7):969-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18615/abstract-text/16831966/pubmed\" id=\"16831966\" target=\"_blank\">",
"        16831966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10246 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.96.59.103-74FB0B1AEA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_11_18615=[""].join("\n");
var outline_f18_11_18615=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219144\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219145\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219173\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219148\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219149\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219150\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6158751\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219124\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219111\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6158752\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219125\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219181\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219171\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219129\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219115\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219167\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219120\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219142\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219121\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6158625\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219152\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6158627\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219133\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219132\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F639157\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219134\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219114\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219128\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10246\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10246|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/46/20196?source=related_link\">",
"      Ropinirole: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_11_18616="Calcium gluconate: Drug information";
var content_f18_11_18616=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Calcium gluconate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/2/5157?source=see_link\">",
"    see \"Calcium gluconate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/13/41175?source=see_link\">",
"    see \"Calcium gluconate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6026083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cal-G [OTC] [DSC];",
"     </li>",
"     <li>",
"      Cal-GLU&trade; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F144682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Calcium Salt;",
"     </li>",
"     <li>",
"      Electrolyte Supplement, Oral;",
"     </li>",
"     <li>",
"      Electrolyte Supplement, Parenteral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F144662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     One gram of calcium gluconate salt is equal to 93 mg of elemental calcium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosages are expressed in terms of the",
"      <span style=\"text-decoration: underline\">",
"       calcium gluconate salt",
"      </span>",
"      (unless otherwise specified as elemental calcium). Dosages expressed in terms of the",
"      <span style=\"text-decoration: underline\">",
"       calcium gluconate salt",
"      </span>",
"      are based on a solution concentration of 100 mg/mL (10%) containing 0.465 mEq (9.3 mg)/mL elemental calcium, except where noted.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dietary Reference Intake for Calcium:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Expressed in terms of elemental calcium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults, Females/Males: RDA:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     19-50 years: 1000 mg",
"     <b>",
"      elemental calcium",
"     </b>",
"     daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;51 years, females: 1200 mg",
"     <b>",
"      elemental calcium",
"     </b>",
"     daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     51-70 years, males: 1000 mg",
"     <b>",
"      elemental calcium",
"     </b>",
"     daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females: Pregnancy/Lactating: RDA: Requirements are the same as in nonpregnant or nonlactating females",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Hypocalcemia:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild (ionized calcium: 4-5 mg/dL [1-1.2 mmol/L]): 1000-2000 mg over 2 hours; asymptomatic patients may be given oral calcium (Ariyan, 2004; French, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate-to-severe (without seizure or tetany; ionized calcium: &lt;4 mg/dL [&lt;1 mmol/L]): 4000 mg over 4 hours (French, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe symptomatic (eg, seizure, tetany): 1000-2000 mg over 10 minutes; repeat every 60 minutes until symptoms resolve (French, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Repeat ionized calcium measurement 6-10 hours after completion of administration. Check for hypomagnesemia and correct if present. Consider continuous infusion if hypocalcemia is likely to recur due to ongoing losses (French, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous infusion: 5-20 mg/kg/hour (Pai, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Cardiac arrest or cardiotoxicity in the presence of hyperkalemia, hypocalcemia, or hypermagnesemia:",
"     </b>",
"     I.V.: 1500-3000 mg over 2-5 minutes (Vanden Hoek, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Routine use in cardiac arrest is not recommended due to the lack of improved survival (Neumar, 2010):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Maintenance electrolyte requirements for parenteral nutrition:",
"     </b>",
"     I.V. (Mirtallo, 2004):",
"     <b>",
"      Note:",
"     </b>",
"     Expressed in terms of",
"     <b>",
"      elemental calcium:",
"     </b>",
"     10-20",
"     <b>",
"      mEq elemental calcium",
"     </b>",
"     daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Calcium channel blocker overdose (unlabeled use):",
"     </b>",
"     <i>",
"      Hypotension/conduction disturbances:",
"     </i>",
"     I.V.: 60-120 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     (Salhanick, 2003)",
"     <b>",
"      or",
"     </b>",
"     60 mg/kg/dose over 5 minutes (maximum: 3000-6000 mg/dose) every 10-20 minutes; may repeat for 3-4 additional doses (Vanden Hoek, 2010; DeWitt, 2004). In life-threatening situations, 1000 mg has been administered every 2-3 minutes until clinical effect is achieved (Buckley, 1994). In one report, 18",
"     <b>",
"      g",
"     </b>",
"     was administered over a 3-hour period (Luscher, 1994).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Hydrofluoric acid burns, treatment (unlabeled route/use):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     SubQ (unlabeled route/use): 5% to 10% solution: 0.5",
"     <b>",
"      mL",
"     </b>",
"     /cm",
"     <sup>",
"      2",
"     </sup>",
"     of burned tissue (Dibbell, 1970; Hatzifotis, 2004; Kirkpatrick, 1995; Krenzelok, 1999). Infiltration should be carried 0.5 cm away from the margin of the injured tissue into the surrounding uninjured areas. Repeat if pain recurs. Local anesthesia may be required to perform procedure; pain resolution is the therapeutic endpoint and if a local anesthetic is utilized, it may be difficult to determine the success of therapy (",
"     <b>",
"      Note: Never",
"     </b>",
"     use calcium chloride for subcutaneous injection).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Intra-arterial (unlabeled route/use): Add 10",
"     <b>",
"      mL",
"     </b>",
"     of a 10% solution to 50 mL of D",
"     <sub>",
"      5",
"     </sub>",
"     W. Infuse over 4 hours into the artery that provides the vascular supply to the affected area (Hatzifotis, 2004; Kirkpatrick, 1995). Pain usually resolves by the end of the infusion; repeat if pain recurs.",
"     <b>",
"      This intervention should be used only by those accustomed to this technique. Extreme care should be taken to avoid the extravasation.",
"     </b>",
"     A poison information center or clinical toxicologist should be consulted prior to implementation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Inhalation (unlabeled route/use): 2.5% nebulization solution: Mix 1",
"     <b>",
"      mL",
"     </b>",
"     of 10% calcium gluconate solution with 4 mL NS to make a 2.5% solution and administer via nebulization (Hatzifotis, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F144675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/13/41175?source=see_link\">",
"      see \"Calcium gluconate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     One gram of calcium gluconate salt is equal to 93 mg of elemental calcium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosages are expressed in terms of the",
"      <span style=\"text-decoration: underline\">",
"       calcium gluconate salt",
"      </span>",
"      (unless otherwise specified as elemental calcium). Dosages expressed in terms of the",
"      <span style=\"text-decoration: underline\">",
"       calcium gluconate salt",
"      </span>",
"      are based on a solution concentration of 100 mg/mL (10%) containing 0.465 mEq (9.3 mg)/mL elemental calcium, except where noted.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dietary Reference Intake for Calcium:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Expressed in terms of elemental calcium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-6 months: Adequate intake: 200 mg",
"     <b>",
"      elemental calcium",
"     </b>",
"     daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7-12 months: Adequate intake: 260 mg",
"     <b>",
"      elemental calcium",
"     </b>",
"     daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years: RDA: 700 mg",
"     <b>",
"      elemental calcium",
"     </b>",
"     daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years: RDA: 1000 mg",
"     <b>",
"      elemental calcium",
"     </b>",
"     daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-18 years: RDA: 1300 mg",
"     <b>",
"      elemental calcium",
"     </b>",
"     daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females: Pregnancy/Lactating: RDA: Requirements are the same as in nonpregnant or nonlactating females",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Hypocalcemia:",
"     </b>",
"     Infants and Children: I.V.: 200-500 mg/kg/day as a continuous infusion or in 4 divided doses (maximum: 2000-3000 mg/dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Cardiac arrest or cardiotoxicity in the presence of hyperkalemia, hypocalcemia, or hypermagnesemia:",
"     </b>",
"     Infants and Children: I.V.: 60-100 mg/kg/dose (maximum: 3000 mg/dose) (Hegenbarth, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Routine use in cardiac arrest is not recommended due to the lack of improved survival (Kleinman, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Maintenance electrolyte requirements for parenteral nutrition:",
"     </b>",
"     Infants and Children (&lt;50 kg): I.V. (Mirtallo, 2004):",
"     <b>",
"      Note:",
"     </b>",
"     Expressed in terms of",
"     <b>",
"      elemental calcium:",
"     </b>",
"     0.5-4",
"     <b>",
"      mEq elemental calcium",
"     </b>",
"     /kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Calcium channel blocker overdose (unlabeled use):",
"     </b>",
"     <i>",
"      Hypotension/conduction disturbances:",
"     </i>",
"     Children: I.V., I.O.: 60 mg/kg/dose administered over 30-60 minutes (Hegenbarth, 2008).",
"     <b>",
"      Note:",
"     </b>",
"     Calcium chloride may provide a more rapid increase of ionized calcium in critically-ill children. Calcium gluconate may be substituted if calcium chloride is not available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Hydrofluoric acid burns, treatment (unlabeled route/use):",
"     </b>",
"     Children: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F144663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     One gram of calcium gluconate salt is equal to 93 mg of elemental calcium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosages are expressed in terms of the",
"      <span style=\"text-decoration: underline\">",
"       calcium gluconate salt",
"      </span>",
"      (unless otherwise specified as elemental calcium). Dosages expressed in terms of the",
"      <span style=\"text-decoration: underline\">",
"       calcium gluconate salt",
"      </span>",
"      are based on a solution concentration of 100 mg/mL (10%) containing 0.465 mEq (9.3 mg)/mL elemental calcium, except where noted.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dietary Reference Intake for Calcium:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Expressed in terms of elemental calcium: RDA",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Males &le;70 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Males &gt;70 years: 1200 mg",
"     <b>",
"      elemental calcium",
"     </b>",
"     daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      All other indications:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F144664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No initial dosage adjustment necessary; however, accumulation may occur with renal impairment and subsequent doses may require adjustment based on serum calcium concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14791789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No initial dosage adjustment necessary; subsequent doses should be guided by serum calcium concentrations. In patients in the anhepatic stage of liver transplantation, equal rapid increases in ionized concentrations occur suggesting that calcium gluconate does not require hepatic metabolism for release of ionized calcium (Martin, 1990).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F144645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cal-G: 700 mg [DSC] [gluten free; equivalent to elemental calcium 65 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cal-GLU&trade;: 515 mg [dye free, sugar free; equivalent to elemental calcium 50 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 10% (10 mL, 50 mL, 100 mL) [equivalent to elemental calcium 9.3 mg (0.465 mEq)/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, oral: (480 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 500 mg [equivalent to elemental calcium 45 mg], 648 mg [equivalent to elemental calcium 60 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F144630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F144649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Administer slowly (~1.5 mL calcium gluconate 10% per minute; not to exceed 200 mg/minute except in emergency situations) through a small needle into a large vein in order to avoid too rapid increases in the serum calcium and extravasation. Not for I.M. administration; not for routine SubQ administration (exception: treatment of hydrofluoric acid burns [unlabeled route/use]).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treatment of hydrofluoric acid burns (unlabeled use):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      SubQ infiltration (unlabeled route):",
"     </i>",
"     Using a 27- or 30-gauge needle, approach the wound from the distal point of injury and infiltrate directly into the affected dermis and subcutaneous tissue. The infiltration should be carried 0.5 cm away from the margin of the injured tissue into the surrounding uninjured areas (Dibbell, 1970). Avoid excessive administration as it can cause compartment syndrome and further exacerbate tissue damage. Following subungual exposure, administer to the affected area via the lateral or volar route through the fat pad (under digital nerve block); administration may also require removal of the nailbed, splitting the distal nail from the nailbed, or trimming the nail to the nailbed to reach the affected area (Kirkpatrick, 1995; Roberts, 1989).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Intra-arterial (unlabeled route):",
"     </i>",
"     Requires radiology to place an arterial catheter in an artery supplying blood to the area of exposure; infuse over four hours (Vance, 1986).",
"     <b>",
"      This intervention should be used only by those accustomed to this technique. Care should be taken to avoid the extravasation.",
"     </b>",
"     A poison information center or clinical toxicologist should be consulted prior to implementation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Inhalation:",
"     </i>",
"     Dilute 10% calcium gluconate solution to a 2.5% solution and administer via nebulization.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F144688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     R, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      20",
"     </sub>",
"     W, LR, NS, R, SL;",
"     <b>",
"      incompatible",
"     </b>",
"     in fat emulsion 10%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Aldesleukin, allopurinol, amifostine, amiodarone, aztreonam, bivalirudin, caffeine citrate, cefazolin, cefepime, ciprofloxacin, cisatracurium, cladribine, dexmedetomidine, dobutamine, docetaxel, doripenem, doxorubicin liposome, enalaprilat, epinephrine, etoposide phosphate, famotidine, fenoldopam, fentanyl, filgrastim, furosemide, gemcitabine, granisetron, heparin, heparin with hydrocortisone sodium succinate, hetastarch in lactated electrolyte injection (Hextend&reg;), labetalol, linezolid, melphalan, micafungin, midazolam, milrinone, nicardipine, nitroprusside, oxaliplatin, pancuronium, piperacillin/tazobactam, potassium chloride, propofol, remifentanil, sargramostim, tacrolimus, telavancin, teniposide, terbutaline, thiotepa, vecuronium, vinorelbine, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, fluconazole, indomethacin, lansoprazole, pemetrexed.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ampicillin, doxapram, meropenem, pantoprazole, prochlorperazine edisylate.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F144648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Treatment of hypocalcemia and conditions secondary to hypocalcemia (eg, tetany, seizures, arrhythmias); treatment of cardiac disturbances secondary to hyperkalemia; adjunctive treatment of rickets, osteomalacia, and magnesium sulfate overdose; decrease capillary permeability in allergic conditions, nonthrombocytopenic purpura, and exudative dermatoses (eg, dermatitis herpetiformis, pruritus secondary to certain drugs)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Dietary calcium supplementation",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F1891175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcium channel blocker overdose; treatment of hydrofluoric acid exposure",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F144690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Calcium gluconate may be confused with calcium glubionate, cupric sulfate",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Calcium gluconate may be confused with calcium chloride.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Confusion with the different intravenous salt forms of calcium has occurred. There is a threefold difference in the primary cation concentration between calcium gluconate (in which 1 g = 4.65 mEq [90 mg] of elemental Ca++) and calcium chloride (in which 1 g = 14 mEq [270 mg] of elemental Ca++).",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Prescribers should specify which salt form is desired. Dosages should be expressed either as mEq, mg, or grams of the salt form.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F144681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular (with rapid I.V. injection): Arrhythmia, bradycardia, cardiac arrest, hypotension, syncope, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Sense of oppression (with rapid I.V. injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypercalcemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Chalky taste",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Tingling sensation (with rapid I.V. injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Heat waves (with rapid I.V. injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Postmarketing and/or case reports: Calcinosis cutis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Oral: Gastrointestinal: Constipation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F144652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ventricular fibrillation; hypercalcemia; concomitant use of I.V. calcium gluconate and ceftriaxone in neonates (risk of precipitation of calcium-ceftriaxone)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F144634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal effects: Constipation, bloating, and gas are common with oral calcium supplements (especially carbonate salt).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperphosphatemia: Use with caution in patients with severe hyperphosphatemia as elevated levels of phosphorus and calcium may result in soft tissue and pulmonary arterial calcium-phosphate precipitation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Use with caution in patients with severe hypokalemia as acute rises in serum calcium levels may result in life-threatening cardiac arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypomagnesemia: Hypomagnesemia is a common cause of hypocalcemia; therefore, correction of hypocalcemia may be difficult in patients with concomitant hypomagnesemia. Evaluate serum magnesium and correct hypomagnesemia (if necessary), particularly if initial treatment of hypocalcemia is refractory.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kidney stones (calcium-containing): Use caution when administering calcium supplements to patients with a history of kidney stones.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with chronic renal failure to avoid hypercalcemia; frequent monitoring of serum calcium and phosphorus is necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ceftriaxone: Ceftriaxone may complex with calcium causing precipitation. Fatal lung and kidney damage associated with calcium-ceftriaxone precipitates has been observed in premature and term neonates. Due to reports of precipitation reaction in neonates, do not coadminister ceftriaxone with calcium-containing solutions, even via separate infusion lines/sites or at different times in any neonate. Ceftriaxone should not be administered simultaneously with any calcium-containing solution via a Y-site in any patient. However, ceftriaxone and calcium-containing solutions may be administered sequentially of one another for use in patients",
"     <b>",
"      other than neonates",
"     </b>",
"     if infusion lines are thoroughly flushed (with a compatible fluid) between infusions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Digoxin: Use with caution in digitalized patients; hypercalcemia may precipitate cardiac arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Minerals/other oral drugs: Calcium administration interferes with absorption of some minerals and drugs; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vitamin D: It is recommended to concomitantly administer vitamin D for optimal calcium absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Absorption: Taking oral calcium (&le;500 mg) with food improves absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aluminum: Solutions may contain aluminum; toxic levels may occur following prolonged administration in premature neonates or patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; I.V. administration: Avoid too rapid I.V. administration (do not exceed 200 mg/minute except in emergency situations); may result in vasodilation, hypotension, bradycardia, arrhythmias, and cardiac arrest. Avoid extravasation; adverse events from extravasation can be devastating (eg, profound tissue necrosis). Monitor the I.V. site closely.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F144639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral calcium supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Acetate: Calcium Salts may enhance the adverse/toxic effect of Calcium Acetate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CefTRIAXone: Calcium Salts (Intravenous) may enhance the adverse/toxic effect of CefTRIAXone. Ceftriaxone binds to calcium forming an insoluble precipitate.  Management: Use of ceftriaxone with calcium-containing solutions within 48 hours of one another is contraindicated in neonates (28 days of age or younger).  In older patients, flush lines with compatible fluid between administration.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Calcium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOBUTamine: Calcium Salts may diminish the therapeutic effect of DOBUTamine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Calcium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., calcium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estramustine: Calcium Salts may decrease the absorption of Estramustine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Calcium Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Calcium Salts may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Calcium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Moxifloxacin (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: Calcium Salts may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and oral calcium salts by at least 2 hours in order to minimize this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Calcium Salts may decrease the serum concentration of Tetracycline Derivatives.  Management: If coadministration of oral calcium with oral tetracyclines can not be avoided, consider separating administration of each agent by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Calcium Salts may diminish the therapeutic effect of Thyroid Products.  Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Calcium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Calcium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Calcium Salts may enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F144642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F1891176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Calcium crosses the placenta. The amount of calcium reaching the fetus is determined by maternal physiological changes. Calcium requirements are the same in pregnant and nonpregnant females (IOM, 2011). Information related to use as an antidote in pregnancy is limited. In general, medications used as antidotes should take into consideration the health and prognosis of the mother (Bailey, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F1891177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F1891178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcium is excreted in breast milk. The amount of calcium in breast milk is homeostatically regulated and not altered by maternal calcium intake. Calcium requirements are the same in lactating and nonlactating females (IOM, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Calcium Gluconate Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (10 mL): $0.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Calcium Gluconate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $6.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $16.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     650 mg (1000): $17.32",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F144646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Serum total calcium: 8.4-10.2 mg/dL (2.1-2.55 mmol/L).",
"     <b>",
"      Note:",
"     </b>",
"     Due to a poor correlation between the serum ionized calcium (free) and total serum calcium, particularly in states of low albumin or acid/base imbalances, direct measurement of ionized calcium is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     In low albumin states, the corrected",
"     <b>",
"      total",
"     </b>",
"     serum calcium may be estimated by the following equation (assuming a normal albumin of 4 g/dL [40 g/L]).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Corrected total calcium (mg/dL) = measured total calcium (mg/mL) + 0.8 [4 - measured serum albumin(g/dL)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Corrected total calcium (mmol/L) = measured total calcium (mmol/L) + 0.02 [40-measured serum albumin (g/L)]",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Biogam Ca (BE);",
"     </li>",
"     <li>",
"      Calcedon (DE);",
"     </li>",
"     <li>",
"      Calcii Gluconas (FI);",
"     </li>",
"     <li>",
"      Calcimusc (HU);",
"     </li>",
"     <li>",
"      Calcinate (PH);",
"     </li>",
"     <li>",
"      Calcio Gluconato (AR, IT);",
"     </li>",
"     <li>",
"      Calcium Braun (DE);",
"     </li>",
"     <li>",
"      Calcium Gluconate (AU);",
"     </li>",
"     <li>",
"      Calcium Gluconicum (BG, PL);",
"     </li>",
"     <li>",
"      Calcium Gluconicum Granulatum (PL);",
"     </li>",
"     <li>",
"      Calcium Pliva (PL);",
"     </li>",
"     <li>",
"      Calcium Polfa (PL);",
"     </li>",
"     <li>",
"      Glucal (ZA);",
"     </li>",
"     <li>",
"      Gluconate de Calcium Lavoisier (FR);",
"     </li>",
"     <li>",
"      Gluconato Calc Fresenius (ES);",
"     </li>",
"     <li>",
"      Gluconato Calcico (ES);",
"     </li>",
"     <li>",
"      Novacalc (NO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F144633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Moderates nerve and muscle performance via action potential threshold regulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     In hydrogen fluoride exposures, calcium gluconate provides a source of calcium ions to complex free fluoride ions and prevent or reduce toxicity; administration also helps to correct fluoride-induced hypocalcemia.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F144651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Requires vitamin D; calcium is absorbed in soluble, ionized form; solubility of calcium is increased in an acid environment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~40%, primarily to albumin (Wills, 1971)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily feces (as unabsorbed calcium salts); urine (20%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      \"2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 10.1: Life-Threatening Electrolyte Abnormalities,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2005, 112:IV121&ndash;5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ariyan CE and Sosa JA, &ldquo;Assessment and Management of Patients With Abnormal Calcium,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2004, 32(4 Suppl):146-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18616/abstract-text/15064673/pubmed\" id=\"15064673\" target=\"_blank\">",
"        15064673",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bailey B, \"Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?\"",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2003, 67(2):133-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18616/abstract-text/12769509/pubmed\" id=\"12769509\" target=\"_blank\">",
"        12769509",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bentur Y, Biran I, and Miller B, &ldquo;Evaluation of the Efficacy of 1% Calcium Gluconate in the Treatment of Hydrofluoric Acid (HF) Eye Burn,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 1995, 33(5):535.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buckley NA, Whyte IM, and Dawson AH, &ldquo;Overdose With Calcium Channel Blockers,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 1994, 308(6944):1639.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18616/abstract-text/8025446/pubmed\" id=\"8025446\" target=\"_blank\">",
"        8025446",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeRoos F, &ldquo;Calcium Channel Blockers,&rdquo; Goldfrank LG, et al, ed,",
"      <i>",
"       Goldfrank&rsquo;s Toxicologic Emergencies",
"      </i>",
"      , 7th ed, New York, (NY):McGraw-Hill Medical Publishing, 2002, 762-74.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeWitt CR and Walsman JC, &ldquo;Pharmacology, Pathophysiology and Management of Calcium Channel Blocker and Beta-Blocker Toxicity,&rdquo;",
"      <i>",
"       Toxicol Rev",
"      </i>",
"      , 2004, 23(4):223-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18616/abstract-text/15898828/pubmed\" id=\"15898828\" target=\"_blank\">",
"        15898828",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dibbell DG, Iverson RE, Jones W, et al, \"Hydrofluoric Acid Burns of the Hand,\"",
"      <i>",
"       J Bone Joint Surg Am",
"      </i>",
"      , 1970, 52(5):931-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18616/abstract-text/5479482/pubmed\" id=\"5479482\" target=\"_blank\">",
"        5479482",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      French S, Subauste J, and Geraci S, &ldquo;Calcium Abnormalities in Hospitalized Patients,&rdquo;",
"      <i>",
"       Southern Med J",
"      </i>",
"      , 2012, 105(4):231-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18616/abstract-text/22475676/pubmed\" id=\"22475676\" target=\"_blank\">",
"        22475676",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hatzifotis M, Williams A, Muller M, et al, \"Hydrofluoric Acid Burns,\"",
"      <i>",
"       Burns",
"      </i>",
"      , 2004, 30(2):156-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18616/abstract-text/15019125/pubmed\" id=\"15019125\" target=\"_blank\">",
"        15019125",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heaney RP, Recker RR, and Saville PD, &ldquo;Menopausal Changes in Calcium Balance Performance,&rdquo;",
"      <i>",
"       J Lab Clin Med",
"      </i>",
"      , 1978, 92(6):953-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18616/abstract-text/739173/pubmed\" id=\"739173\" target=\"_blank\">",
"        739173",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hegenbarth MA and the American Academy of Pediatrics Committee on Drugs, &ldquo;Preparing for Pediatric Emergencies: Drugs to Consider,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(2):433-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18616/abstract-text/18245435/pubmed\" id=\"18245435\" target=\"_blank\">",
"        18245435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Howarth DM, Dawson AH, Smith AJ, et al, &ldquo;Calcium Channel Blocking Drug Overdose: An Australian Series,&rdquo;",
"      <i>",
"       Hum Exp Toxicol",
"      </i>",
"      , 1994, 13(3):161-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18616/abstract-text/7909677/pubmed\" id=\"7909677\" target=\"_blank\">",
"        7909677",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Calcium and Vitamin D",
"      </i>",
"      , Washington, DC: The National Academies Press, 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Isbister GK, &ldquo;Continuous Calcium Chloride Infusion for Massive Nifedipine Overdose,&rdquo;",
"      <i>",
"       Emerg Med J",
"      </i>",
"      , 2002, 19(4):355-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18616/abstract-text/12101159/pubmed\" id=\"12101159\" target=\"_blank\">",
"        12101159",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kirkpatrick JJ and Burd DAR, &ldquo;An Algorithmic Approach to the Treatment of Hydrofluoric Acid Burns,&rdquo;",
"      <i>",
"       Burns",
"      </i>",
"      , 1995, 21(7):495-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18616/abstract-text/8540974/pubmed\" id=\"8540974\" target=\"_blank\">",
"        8540974",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kleinman ME, Chameides L, Schexnayder SM, et al, &ldquo;Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):876-908.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18616/abstract-text/20956230/pubmed\" id=\"20956230\" target=\"_blank\">",
"        20956230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Krenzelok EP, \"Hydrofluoric Acid Exposures,\"",
"      <i>",
"       Clinical Environmental Health and Toxic Exposures",
"      </i>",
"      , 2nd ed, Sullivan JB and Krieger GR, eds, Philadelphia, PA: Lippincott Williams &amp; Wilkins, 1999, 798-806.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lam YM, Tse HF, and Lau CP, &ldquo;Delayed Asystolic Cardiac Arrest After Diltiazem Overdose: Resuscitation With High Dose Intravenous Calcium,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2001, 119(4):1280-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18616/abstract-text/11296202/pubmed\" id=\"11296202\" target=\"_blank\">",
"        11296202",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Luscher TF, Noll G, and Sturmer T, &ldquo;Calcium Gluconate in Severe Verapamil Intoxication,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1994, 330(10):718-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18616/abstract-text/8107735/pubmed\" id=\"8107735\" target=\"_blank\">",
"        8107735",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martin TJ, Kang Y, Robertson KM, et al, &ldquo;Ionization and Hemodynamic Effects of Calcium Chloride and Calcium Gluconate in the Absence of Hepatic Function,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1990, 73(1):62-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18616/abstract-text/2360741/pubmed\" id=\"2360741\" target=\"_blank\">",
"        2360741",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Millard TP, Harris AJ, and MacDonald DM, \"Calcinosis Cutis Following Intravenous Infusion of Calcium Gluconate,\"",
"      <i>",
"       Br J Dermatol",
"      </i>",
"      , 1999, Jan;140(1):184-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18616/abstract-text/10215803/pubmed\" id=\"10215803\" target=\"_blank\">",
"        10215803",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mirtallo J, Canada T, Johnson D, et al, \"Safe Practices for Parenteral Nutrition,\"",
"      <i>",
"       JPEN J Parenter Enteral Nutr",
"      </i>",
"      , 2004, 28(6):S39-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18616/abstract-text/15568296/pubmed\" id=\"15568296\" target=\"_blank\">",
"        15568296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18616/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neumar RW, Otto CW, Link MS, et al, &ldquo;Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):729-67.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pai AB, &ldquo;Chapter 59: Disorders of Calcium and Phosphorus Homeostasis,&rdquo;",
"      <i>",
"       Pharmacotherapy: A Pathophysiologic Approach",
"      </i>",
"      , 8th ed, Talbert RL, DiPiro JT, Matzke GR, et al, eds, New York, NY:McGraw-Hill, 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pearigen PD and Benowitz NL, &ldquo;Poisoning Due to Calcium Antagonists: Experience With Verapamil, Diltiazem, and Nifedipine,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1991, 6(6):408-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18616/abstract-text/1793522/pubmed\" id=\"1793522\" target=\"_blank\">",
"        1793522",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Recker RR, &ldquo;Calcium Absorption and Achlorhydria,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1985, 313(2):70-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18616/abstract-text/4000241/pubmed\" id=\"4000241\" target=\"_blank\">",
"        4000241",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roberts JR and Merigian KS, \"Acute Hydrofluoric Acid Exposure,\"",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1989, 7(1):125-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18616/abstract-text/2914038/pubmed\" id=\"2914038\" target=\"_blank\">",
"        2914038",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Salhanick SD and Shannon MW, &ldquo;Management of Calcium Channel Antagonist Overdose,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 2003, 26(2):65-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18616/abstract-text/12534324/pubmed\" id=\"12534324\" target=\"_blank\">",
"        12534324",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schmidt MJ and Bryant SM, \"Hydrofluoric Acid Burn to Penis,\"",
"      <i>",
"       Clin Toxicol (Phila)",
"      </i>",
"      , 2007, 45(6):732.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18616/abstract-text/17849253/pubmed\" id=\"17849253\" target=\"_blank\">",
"        17849253",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trujillo M, Guerrero J, Fragachan C, et al, \"Pharmacologic Antidotes in Critical Care Medicine: A Practical Guide for Drug Administration,",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1998, 26(2):377-91.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vance MV, Curry SC, Kunkel DB, et al, &ldquo;Digital Hydrofluoric Acid Burns: Treatment With Intraarterial Calcium Infusion,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1986, 15(8):890-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18616/abstract-text/3740574/pubmed\" id=\"3740574\" target=\"_blank\">",
"        3740574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vanden Hoek TL, Morrison LJ, Shuster M, et al, &ldquo;Part 12: Cardiac Arrest in Special Situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):829-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18616/abstract-text/20956228/pubmed\" id=\"20956228\" target=\"_blank\">",
"        20956228",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wills MR and Lewin MR, &ldquo;Plasma Calcium Fractions and the Protein-Binding of Calcium in Normal Subjects and in Patients With Hypercalcemia and Hypocalcemia,&rdquo;",
"      <i>",
"       J Clin Pathol",
"      </i>",
"      , 1971, 24(9):856-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/11/18616/abstract-text/5139991/pubmed\" id=\"5139991\" target=\"_blank\">",
"        5139991",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Worthley LI and Phillips PJ, &ldquo;Intravenous Calcium Salts,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1980, 2(8186):149.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9190 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-12D3B89698-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_11_18616=[""].join("\n");
var outline_f18_11_18616=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6026083\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144682\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144662\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144675\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144663\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144664\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14791789\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144645\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144630\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144649\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144688\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144648\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1891175\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144690\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144681\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144652\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144634\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298941\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144639\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144642\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1891176\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1891177\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1891178\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323034\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144646\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038547\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144633\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144651\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9190\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9190|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/2/5157?source=related_link\">",
"      Calcium gluconate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/13/41175?source=related_link\">",
"      Calcium gluconate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_11_18617="Genetic and cellular therapy in heart failure and myocardial infarction";
var content_f18_11_18617=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Genetic and cellular therapy in heart failure and myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/11/18617/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/11/18617/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/11/18617/contributors\">",
"     Michael Simons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/11/18617/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/11/18617/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/11/18617/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/11/18617/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/11/18617/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/11/18617/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic modulation of ventricular function may offer a novel therapeutic strategy for heart failure (HF). In animal models, it is feasible to deliver transgenes via direct intramyocardial injection, ex vivo perfusion, or a transluminal intracoronary approach [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Another approach is cell-based cardiac repair, also called cellular cardiomyoplasty, which involves the transplantation of cells that may become cardiomyocytes into the diseased heart [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Both approaches are currently experimental and controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gene therapy for HF has been evaluated in animal models, but has not yet been shown to be of clinical value in humans. Several molecular targets have been selected based upon the known pathophysiology of HF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Sarcoplasmic reticulum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiomyocytes isolated from failing human hearts demonstrate systolic contractile and diastolic relaxation abnormalities, which are associated with abnormal calcium homeostasis, including reduced sarcoplasmic calcium release, reduced activity of the sarcoplasmic reticulum calcium ATPase pump (SERCA2a) activity, elevated diastolic calcium, and a reduced rate of calcium removal.",
"   </p>",
"   <p>",
"    These observations have led to the suggestion that reduced activity of SERCA2a may play a central role in the development and progression of HF. Reduced SERCA2a may be mediated, at least in part, by phospholamban, a SERCA2a inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10632?source=see_link\">",
"     \"Excitation-contraction coupling in myocardium\"",
"    </a>",
"    .) Supporting this concept is a report of a phospholamban mutation causing a familial human cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=see_link\">",
"     \"Genetics of dilated cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In animal models of HF, a number of approaches have been used to improve the",
"    <span class=\"nowrap\">",
"     phospholamban/SERCA2a",
"    </span>",
"    ratio, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adenoviral transfer of antisense phospholamban or of a mutant phospholamban to reduce its expression [",
"      <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/7,8,10,11\">",
"       7,8,10,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adenoviral transfer of the gene coding for SERCA2a to increase its expression [",
"      <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These approaches may both prevent the development of HF [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/7\">",
"     7",
"    </a>",
"    ] and improve left ventricular function and survival [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/10,11,13\">",
"     10,11,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The safety and potential clinical utility of SERCA gene transfer to the myocardium was evaluated by CUPID, a phase 2 randomized trial of intracoronary administration of adeno-associated virus type I",
"    <span class=\"nowrap\">",
"     a/SERCA2a",
"    </span>",
"    or placebo in 39 patients with severe HF [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/14\">",
"     14",
"    </a>",
"    ]. At six months, there were no untoward effects, and several measures of efficacy were improved or stabilized, including functional classification, exercise capacity, natriuretic peptide levels, and left ventricular end-systolic volume. While numerous animal studies have suggested the potential utility of gene therapy in HF, CUPID provides some of the first data to support the clinical utility of this approach in humans with HF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Beta adrenergic receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the failing myocardium, the density of beta-adrenergic receptors is reduced, often by as much as 50 percent, and there is a reduction in the responsiveness of the remaining receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link&amp;anchor=H3#H3\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\", section on 'Indications for therapy'",
"    </a>",
"    .) In an animal study, the intracoronary delivery of an adenovirus containing the beta-2 adrenergic receptor gene resulted in a 10-fold overexpression of the beta-2 adrenergic receptor in the left ventricle three days after gene delivery; there was also improved left ventricular contractility at rest and during an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the improvement in contractility is dependent upon the extent of overexpression of the receptor, and higher levels of expression may lead to direct adverse effects on the myocardium. As an example, contractility was increased in transgenic mice with a 60-fold overexpression of the receptor, whereas a &ge;100-fold over-expression led to fibrotic cardiomyopathy and HF [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another approach is augmenting beta-adrenergic receptor responsiveness by delivery of an adenovirus containing the gene for the inhibitor of beta-adrenergic receptor kinase, which desensitizes the beta-receptors by phosphorylation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Adenylyl cyclase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The amount of adenylyl cyclase is the primary limiting factor of a cell's ability to generate cyclic AMP in response to beta adrenergic receptor stimulation. In a transgenic animal model of cardiomyopathy, the overexpression of adenylyl cyclase type VI increased the generation of cyclic AMP and responsiveness to catecholamines, improved left ventricular function, reduced hypertrophy, and improved survival [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In another animal study, the intracoronary injection of a recombinant adenovirus encoding for adenylyl cyclase type VI resulted in a significant increase in adenylyl cyclase protein content and stimulated cyclic AMP levels [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/21\">",
"     21",
"    </a>",
"    ]. Six days after gene transfer there was a significant increase in left ventricular contractility (peak",
"    <span class=\"nowrap\">",
"     dP/dt),",
"    </span>",
"    which persisted for at least 57 days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10632?source=see_link\">",
"     \"Excitation-contraction coupling in myocardium\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     V2 vasopressin receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The V2 vasopressin receptor, which is normally expressed only in the kidney, promotes activation of adenyl cyclase, and might therefore be expected to have a positive inotropic effect if expressed in the myocardium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16552?source=see_link\">",
"     \"Chapter 6B: Antidiuretic hormone and water balance\"",
"    </a>",
"    .) The observation that levels of arginine vasopressin (antidiuretic hormone) are increased in patients with HF suggests that expression of the V2 receptor in the myocardium may cause an increase in contractility, a result of the increased arginine vasopressin levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32455?source=see_link\">",
"     \"Pathophysiology of heart failure: Neurohumoral adaptations\"",
"    </a>",
"    .) This was examined in an animal study that performed gene transfer with a recombinant adenovirus for the human V2 vasopressin receptor into the myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/22\">",
"     22",
"    </a>",
"    ]. The systemic administration of vasopressin resulted in an increase in myocardial contractility in treated animal, but not in controls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CELLULAR CARDIOMYOPLASTY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cellular cardiomyoplasty involves myogenic cell grafting within the myocardium to limit any consequences from the loss of contractile function of a damaged left ventricle [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Organ transplantation as a model",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies from clinical heart and bone marrow transplantation provide evidence that primitive cell migration and proliferation can occur within the myocardium. This phenomenon is illustrated in two reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of eight hearts from female donors transplanted into male recipients, samples of atrial and ventricular myocardium from the donor heart showed a high number of primitive cells that originated from the recipient, as established by the presence of a Y chromosome (ie, chimerism) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/23\">",
"       23",
"      </a>",
"      ]. There was a high degree of differentiation of these cells, which formed new myocytes, coronary arterioles, and capillaries.",
"     </li>",
"     <li>",
"      In another study, four hearts were explanted at autopsy from women who had previously undergone sex-mismatched bone marrow transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/24\">",
"       24",
"      </a>",
"      ]. A Y chromosome was detected in 0.23 percent of the cardiomyocytes in these hearts (and in none of four gender-matched control hearts), suggesting that bone marrow-derived progenitors from the male donor marrow had populated the female recipient myocardium.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, it is not clear that transdifferentiation of bone marrow cells into cardiac myocytes actually occurs. Many technical challenges underlie accurate interpretation of data from human transplantation subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/25\">",
"     25",
"    </a>",
"    ]. In a mouse model of 145 transplants, genetic tools were used to follow cell fate directly [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/26\">",
"     26",
"    </a>",
"    ]. In this model, there was no evidence of transdifferentiation. Chimerism probably accounts for at least some of the \"transdifferentiation\" events noted in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro and in vivo animal studies have shown that neonatal cardiomyocytes, skeletal myoblasts, hematopoietic stem cells, and marrow mesenchymal stem cells or stromal cells that are transplanted into a normal or infarcted myocardium or a dilated cardiomyopathy remain viable for months and can proliferate and differentiate into mature cardiomyocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/3,4,28-36\">",
"     3,4,28-36",
"    </a>",
"    ]. Bone marrow-derived cells express functional adrenergic and muscarinic receptors after differentiating into cardiomyocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/37\">",
"     37",
"    </a>",
"    ]. The formation of cardiac tissue, an improvement in left ventricular remodeling, and preservation of left ventricular function have all been suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/30,32,33,36\">",
"     30,32,33,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar improvement in left ventricular remodeling and preservation of left ventricular function were observed in a preliminary report of transplantation of adult human epicardium-derived cells (EPDCs) into ischemic mouse myocardium, although the cells differentiated into a myoendothelial phenotype rather than cardiomyocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Mechanism of benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;The improvements in myocardial function cited above in animals have been replicated with hematopoietic stems cells and autologous skeletal myoblasts in humans. However, the mechanism of benefit is uncertain. As noted above, some studies have demonstrated that hematopoietic stem cells do not transdifferentiate into cardiac myocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/26,39\">",
"     26,39",
"    </a>",
"    ], except for a low rate of cell fusion events [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/39\">",
"     39",
"    </a>",
"    ], and autologous skeletal myoblasts can contract but do not transdifferentiate into cardiomyocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/4,40\">",
"     4,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An emerging hypothesis to explain the benefit from cellular therapy is a paracrine effect in which transplanted cells produce growth factors, cytokines, and other signaling molecules that result in improved overall myocardial function via mechanisms such as increased myocardial perfusion due to angiogenesis, prolongation of the survival of myocytes or other cells, or activation of progenitor cells within the myocardium that can differentiate into new cardiomyocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/4,41\">",
"     4,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the heart was traditionally thought to lack capacity for regeneration, observations using carbon-14 dating suggest that cardiomyocytes renew at a low rate throughout life, with fewer than 50 percent of cardiomyocytes renewing over an average life span [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/42\">",
"     42",
"    </a>",
"    ]. Potential sources for cardiomyocytes renewal include cardiomyocytes that reenter the cell cycle or stem cells. Human cardiac stem cells have been identified in the myocardium that can differentiate into cardiomyocytes and to a lesser extent into smooth muscle cells and endothelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Other cell sources that may have the potential to differentiate into cardiomyocytes are bone marrow derived mesenchymal stem cells [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/34,35,37,45\">",
"     34,35,37,45",
"    </a>",
"    ], and embryonic stem cells [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hematopoietic stem cell therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematopoietic stem cells are bone marrow-derived cells capable of differentiating into a variety of cell types. Such cells may be obtained directly from the bone marrow or, using apheresis techniques, from peripheral blood usually after stimulation with granulocyte-colony stimulating factor (G-CSF). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An increasing number of studies have used hematopoietic stem cells to repopulate the myocardium of patients with an acute myocardial infarction (MI) or ischemic cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/3,4,49-60\">",
"     3,4,49-60",
"    </a>",
"    ]. As mentioned in the previous section, the benefit is not due to transdifferentiation into cardiomyocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/26,39\">",
"     26,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Acute MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early unblinded studies suggested a benefit from stem cell therapy following acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/52-59,61\">",
"     52-59,61",
"    </a>",
"    ]. However, more recent blinded randomized trials have produced mixed results. The mechanisms of potential benefit remain uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the BOOST trial, 60 patients with an acute MI who had undergone percutaneous coronary intervention (PCI) were randomly assigned to bone marrow cell harvest and intracoronary infusion into the infarct-related artery or a control group [",
"      <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/52\">",
"       52",
"      </a>",
"      ]. The left ventricular ejection fraction (LVEF) was similar in the bone marrow and control groups at baseline post-MI (51.3 and 50.0 percent, respectively). After six months, the increase in mean global LVEF was significantly greater in the bone marrow group (6.7 versus 0.7 percentage points in controls). However, this difference was no longer significant at late follow-up at 18 months (5.9 versus 3.1 percentage points), suggesting that the benefit was limited to acceleration of LVEF recovery [",
"      <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/63\">",
"       63",
"      </a>",
"      ]. Bone marrow cell infusion did not increase the risk of adverse clinical events, in-stent restenosis, or proarrhythmia.",
"     </li>",
"     <li>",
"      The benefits on left ventricular function were less prominent in another trial of similar design in which 67 patients who underwent successful primary PCI for an ST elevation MI were randomly assigned to bone marrow cell harvest and intracoronary infusion of isolated bone marrow stem cells into the infarct-related artery or a control group [",
"      <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/59\">",
"       59",
"      </a>",
"      ]. At four months, there was no difference between the two groups in LVEF. However, the patients who underwent stem cell transfer had a significant 28 percent reduction in infarct size and better recovery of regional systolic function, changes that may reflect improved infarct remodeling.",
"     </li>",
"     <li>",
"      The largest experience comes from the REPAIR-AMI trial [",
"      <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/61\">",
"       61",
"      </a>",
"      ]. In this multicenter trial, 204 patients who underwent primary PCI after an ST elevation MI were randomly assigned to receive an intracoronary infusion into the infarct-related artery of autologous mononuclear progenitor cells or a placebo medium three to six days after the MI. The primary end point, the absolute increase in LVEF at four months assessed by serial LV angiograms, was significantly higher with active therapy (5.5 versus 3.0 percent with placebo). Subgroup analyses found that the benefit was limited to patients with a baseline LVEF &lt;49 percent and to those treated more than five days after the MI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Doppler Substudy of REPAIR-AMI evaluated the effect of intracoronary infusion into the infarct-related artery of progenitor cells on coronary blood flow regulation in 30 patients who received progenitor cells as compared to 28 patients who received placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/64\">",
"     64",
"    </a>",
"    ]. At four month follow-up, coronary flow reserve in the infarct artery was markedly increased to normal in the progenitor cell-treated patients compared with only a moderate improvement in the placebo group.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In contrast to the above trials that showed short term benefit, the ASTAMI trial did not demonstrate improved outcomes with cardiomyoplasty [",
"      <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/65\">",
"       65",
"      </a>",
"      ]. 100 patients with an anterior MI undergoing primary PCI were randomly assigned to intracoronary bone marrow mononuclear cell infusion or control. Serial imaging with multiple modalities in each patient (echocardiography, nuclear SPECT imaging and cardiac magnetic resonance imaging) at baseline and at six months found no differences in LVEF or infarct size in the two groups.",
"     </li>",
"     <li>",
"      The potential value of granulocyte-colony stimulating factor (G-CSF) in comparison to the combination of G-CSF and stem cell infusion was assessed in the MAGIC trial [",
"      <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/53\">",
"       53",
"      </a>",
"      ]. 27 patients with an acute MI undergoing PCI were randomly assigned to stem cell mobilization with G-CSF followed by stem cell apheresis and intracoronary reinfusion, to G-CSF alone, or to a control group. Six-month follow-up data in 10 of the study patients demonstrated an improvement in LVEF with stem cell infusion (from 48.7 to 55.1 percent) but not with G-CSF alone. Stem cell infusion also increased treadmill exercise time and reduced the size of the myocardial perfusion defect. However, administration of G-CSF was associated with an unexpectedly high rate of in-stent restenosis of the culprit lesion. A similar lack of benefit has been shown in other trials of G-CSF alone in patients with an acute MI (see",
"      <a class=\"local\" href=\"#H14\">",
"       'G-CSF or GM-CSF alone'",
"      </a>",
"      below) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/66-68\">",
"       66-68",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Ischemic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stem cell therapy has also been evaluated in patients with ischemic cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/60,69-73\">",
"     60,69-73",
"    </a>",
"    ]. The potential efficacy was illustrated in a study in which bone marrow mononuclear cells were injected directly into areas of viable but dysfunctional myocardium in 14 patients with ischemic cardiomyopathy and HF [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/72\">",
"     72",
"    </a>",
"    ]. An additional seven patients served as controls. At two months, there was a significant reduction in the area of reversible ischemia (from 15 to 6 percent of total myocardium) and a significant increase in LVEF (from 30 to 36 percent) in the treated patients but not in controls. Electromechanical mapping demonstrated significant mechanical improvement in the injected segments at four months.",
"   </p>",
"   <p>",
"    Similar findings were noted in a nonblinded observational study of 18 consecutive patients who had had a myocardial infarction five months to nine years previously; these patients were compared to a representative control group that did not receive cellular therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/60\">",
"     60",
"    </a>",
"    ]. At three months after intracoronary transplantation of autologous bone marrow mononuclear cells, infarct size was reduced by 30 percent, the LVEF increased by 15 percent, and infarction wall movement velocity increased by 57 percent. There were no significant changes in the control group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     G-CSF or GM-CSF alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lack of benefit and possible adverse outcomes with G-CSF alone in the MAGIC trial cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/53\">",
"     53",
"    </a>",
"    ] are consistent with other studies of G-CSF or GM-CSF alone that showed no long-term efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/66-68\">",
"     66-68",
"    </a>",
"    ] and a possible increase in the risk of coronary ischemia and acute coronary syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/68,74\">",
"     68,74",
"    </a>",
"    ]. In contrast, the FIRSTLINE-AMI found a significantly higher LVEF at rest at four months with G-CSF therapy (54 versus 43 percent) and other benefits, including a greater increase in viable myocardium in the infarct territory (11 versus 0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/54\">",
"     54",
"    </a>",
"    ]. However, this trial was unblinded and included only 50 patients.",
"   </p>",
"   <p>",
"    The largest experience comes from the REVIVAL-2 trial in which 114 patients with an acute ST elevation involving at least 5 percent of the left ventricle underwent successful reperfusion by primary PCI (most with bare metal stents) and five days later were randomly assigned to G-CSF (10",
"    <span class=\"nowrap\">",
"     &micro;g/kg)",
"    </span>",
"    or placebo daily for five days [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/66\">",
"     66",
"    </a>",
"    ]. Patients with heart failure, electrical or hemodynamic instability, or a prior MI were excluded. Despite a marked increase in circulating stem cells, there was no difference between the groups in the primary end point &mdash; a reduction in infarct size at four to six months, as assessed by radionuclide myocardial perfusion imaging (6.2 versus 4.9 percent with placebo) &mdash; or in the secondary end points of improvement in LVEF (+0.5 versus +2.0 percent) and angiographic restenosis (35 versus 31 percent).",
"   </p>",
"   <p>",
"    A similar lack of benefit was noted in the STEMI trial in which 78 patients with an STEMI who underwent successful primary PCI were randomly assigned to G-CSF (10",
"    <span class=\"nowrap\">",
"     &micro;g/kg)",
"    </span>",
"    or placebo daily for six days [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/67\">",
"     67",
"    </a>",
"    ]. At six months, there was no difference between the two groups in the primary end point of change in systolic wall thickening on cardiac magnetic resonance imaging (17 percent improvement), LVEF, or target vessel revascularization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Autologous skeletal myoblast transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are increasing data on the possible efficacy of transplantation of autologous skeletal myoblasts into a postinfarction scar during coronary artery bypass graft surgery (CABG) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/75-79\">",
"     75-79",
"    </a>",
"    ], during implantation of a left ventricular assist device (LVAD) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/78,80\">",
"     78,80",
"    </a>",
"    ], or using a percutaneous transendocardial injection catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/81\">",
"     81",
"    </a>",
"    ]. As noted above, the benefit is not due to transdifferentiation into cardiomyocytes although autologous skeletal myoblasts can contract [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/4,40\">",
"     4,40",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Mechanism of benefit'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In a multicenter study of this still investigational procedure, 30 patients with ischemic cardiomyopathy underwent autologous skeletal myoblast transplantation at the time of CABG (24 patients) or LVAD implantation (six patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/78\">",
"     78",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The LVEF, measured by echocardiography, increased from 28 percent at baseline to 35 percent at one year and 36 percent at two years. However, this benefit might have been due to CABG, rather than the skeletal myoblasts.",
"     </li>",
"     <li>",
"      Follow-up positron emission tomography showed new areas of glucose uptake within the scar.",
"     </li>",
"     <li>",
"      Histologic evaluation in the four patients in the LVAD group who underwent heart transplantation demonstrated survival and engraftment of skeletal myoblasts within the infarcted myocardium. Similar findings were noted in another report of LVAD as a bridge to transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/80\">",
"       80",
"      </a>",
"      ]. In three of four patients undergoing explant of the device, skeletal muscle cell survival and differentiation into mature myofibers was demonstrated in heavily scarred myocardial tissue.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A pilot trial using a novel percutaneous transendocardial injection catheter evaluated five patients with symptomatic HF after an anterior MI [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/81\">",
"     81",
"    </a>",
"    ]. Skeletal myoblasts were injected into areas of infarction; the injection sites were selected using endocardial electroanatomical mapping. The mean LVEF increased from 36 percent at baseline to 41 percent at three months and 45 percent at six months. There was also a significant increase in regional wall thickening in the target areas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39289?source=see_link&amp;anchor=H19#H19\">",
"     \"Electrophysiologic cardiac mapping: Techniques\", section on 'Electroanatomical mapping'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Potential risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;The limited clinical data available do not permit a full assessment of the potential risks of cellular cardiomyoplasty as a therapeutic modality. Three concerns are ventricular tachyarrhythmia and a possible increase in in-stent restenosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Ventricular tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Episodes of ventricular tachycardia occur in many patients after myoblast injection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/77,78,81,82\">",
"     77,78,81,82",
"    </a>",
"    ]. As a result, an implantable cardioverter-defibrillator is now routinely required for myoblast studies.",
"   </p>",
"   <p>",
"    The pathogenesis of these arrhythmias is not well understood. An experimental model used cocultures of mesenchymal stem cells and neonatal rat ventricular myocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/83\">",
"     83",
"    </a>",
"    ]. Reentrant arrhythmias could be induced in most cocultures, and functional gap junctions were noted in the mesenchymal stem cells. It was suggested that reentry probably resulted from increased tissue heterogeneity due to electrical coupling of inexcitable mesenchymal stem cells with ventricular myocytes.",
"   </p>",
"   <p>",
"    A similar mechanism may be involved with skeletal muscle cells, which are electrically isolated because of the absence of gap junctions. In an experimental model, genetic modification of myoblasts to express connexin43, a gap junction protein, reduced arrhythmogenicity in coculture of skeletal myoblasts and cardiomyocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     In-stent restenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, there are conflicting data as to whether stem cell therapy is [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/53\">",
"     53",
"    </a>",
"    ] or is not [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/54\">",
"     54",
"    </a>",
"    ] associated with an increase in in-stent restenosis and whether there is [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/68,74\">",
"     68,74",
"    </a>",
"    ] or is not [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/54\">",
"     54",
"    </a>",
"    ] an increase in the risk of coronary ischemia and acute coronary syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/68,74\">",
"     68,74",
"    </a>",
"    ]. In a study in dogs, intracoronary injection of bone marrow-derived stem cells was associated with histologic evidence of microinfarction of the myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    &nbsp;Bone formation &mdash; A mouse study found that injection of mesenchymal stem cells or unfractionated bone marrow cells into myocardial infarction led to frequent calcifications",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ossifications that were not found after injection of purified hematopoietic progenitors, fibroblasts or vehicle only [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/86\">",
"     86",
"    </a>",
"    ]. These findings suggest that development of transplanted mesenchymal stem cells is not restricted by the surrounding tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Perivascular fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mouse study found that bone marrow derived cells differentiated into myofibroblasts in fibrotic perivascular spaces in addition to participating in cardiac hypertrophy via cell fusion and transdifferentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18617/abstract/87\">",
"     87",
"    </a>",
"    ]. Observation of fibrosis in this study and bone formation in the preceding study suggest that undesired forms of cell differentiation may occur when bone marrow cells are mobilized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Experimental approaches for gene therapy for heart failure have focused on several molecular targets including the sarcoplasmic reticulum, the beta adrenergic receptor, adenylyl cyclase, and the V2 vasopressin receptor. The efficacy of these approaches has not been established. A preliminary clinical study suggested possible benefit from sarcoplasmic reticulum calcium ATPase pump (SERCA2a) gene transfer. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Gene therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cellular cardiomyoplasty is a technique that has been investigated as a means of reducing myocardial infarct size and improving cardiac function in patients with ischemic heart disease. However, the efficacy and mechanism of potential benefit of this approach have not been established and potential risks have not been adequately assessed. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Cellular cardiomyoplasty'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/1\">",
"      Maurice JP, Hata JA, Shah AS, et al. Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary beta2-adrenergic receptor gene delivery. J Clin Invest 1999; 104:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/2\">",
"      French BA, Mazur W, Geske RS, Bolli R. Direct in vivo gene transfer into porcine myocardium using replication-deficient adenoviral vectors. Circulation 1994; 90:2414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/3\">",
"      Lee MS, Makkar RR. Stem-cell transplantation in myocardial infarction: a status report. Ann Intern Med 2004; 140:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/4\">",
"      Murry CE, Field LJ, Menasch&eacute; P. Cell-based cardiac repair: reflections at the 10-year point. Circulation 2005; 112:3174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/5\">",
"      de Muinck ED, Thompson C, Simons M. Progress and prospects: cell based regenerative therapy for cardiovascular disease. Gene Ther 2006; 13:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/6\">",
"      Oettgen P, Boyle AJ, Schulman SP, Hare JM. Cardiac Stem Cell Therapy. Need for Optimization of Efficacy and Safety Monitoring. Circulation 2006; 114:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/7\">",
"      Minamisawa S, Hoshijima M, Chu G, et al. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 1999; 99:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/8\">",
"      del Monte F, Harding SE, Dec GW, et al. Targeting phospholamban by gene transfer in human heart failure. Circulation 2002; 105:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/9\">",
"      Schmitt JP, Kamisago M, Asahi M, et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 2003; 299:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/10\">",
"      Hoshijima M, Ikeda Y, Iwanaga Y, et al. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 2002; 8:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/11\">",
"      Iwanaga Y, Hoshijima M, Gu Y, et al. Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. J Clin Invest 2004; 113:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/12\">",
"      Harding SE, Schmidt U, Matsui T, et al. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation 1999; 100:2308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/13\">",
"      del Monte F, Williams E, Lebeche D, et al. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. Circulation 2001; 104:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/14\">",
"      Jessup M, Greenberg B, Mancini D, et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 2011; 124:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/15\">",
"      Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 1982; 307:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/16\">",
"      Shah AS, Lilly RE, Kypson AP, et al. Intracoronary adenovirus-mediated delivery and overexpression of the beta(2)-adrenergic receptor in the heart : prospects for molecular ventricular assistance. Circulation 2000; 101:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/17\">",
"      Liggett SB, Tepe NM, Lorenz JN, et al. Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation 2000; 101:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/18\">",
"      Shah AS, White DC, Emani S, et al. In vivo ventricular gene delivery of a beta-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. Circulation 2001; 103:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/19\">",
"      Roth DM, Gao MH, Lai NC, et al. Cardiac-directed adenylyl cyclase expression improves heart function in murine cardiomyopathy. Circulation 1999; 99:3099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/20\">",
"      Roth DM, Bayat H, Drumm JD, et al. Adenylyl cyclase increases survival in cardiomyopathy. Circulation 2002; 105:1989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/21\">",
"      Lai NC, Roth DM, Gao MH, et al. Intracoronary delivery of adenovirus encoding adenylyl cyclase VI increases left ventricular function and cAMP-generating capacity. Circulation 2000; 102:2396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/22\">",
"      Weig HJ, Laugwitz KL, Moretti A, et al. Enhanced cardiac contractility after gene transfer of V2 vasopressin receptors In vivo by ultrasound-guided injection or transcoronary delivery. Circulation 2000; 101:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/23\">",
"      Quaini F, Urbanek K, Beltrami AP, et al. Chimerism of the transplanted heart. N Engl J Med 2002; 346:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/24\">",
"      Deb A, Wang S, Skelding KA, et al. Bone marrow-derived cardiomyocytes are present in adult human heart: A study of gender-mismatched bone marrow transplantation patients. Circulation 2003; 107:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/25\">",
"      Chien KR. Stem cells: lost in translation. Nature 2004; 428:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/26\">",
"      Murry CE, Soonpaa MH, Reinecke H, et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 2004; 428:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/27\">",
"      Minami E, Laflamme MA, Saffitz JE, Murry CE. Extracardiac progenitor cells repopulate most major cell types in the transplanted human heart. Circulation 2005; 112:2951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/28\">",
"      Scorsin M, Marotte F, Sabri A, et al. Can grafted cardiomyocytes colonize peri-infarct myocardial areas? Circulation 1996; 94:II337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/29\">",
"      Jackson KA, Majka SM, Wang H, et al. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest 2001; 107:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/30\">",
"      Scorsin M, Hag&egrave;ge A, Vilquin JT, et al. Comparison of the effects of fetal cardiomyocyte and skeletal myoblast transplantation on postinfarction left ventricular function. J Thorac Cardiovasc Surg 2000; 119:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/31\">",
"      Wang JS, Shum-Tim D, Galipeau J, et al. Marrow stromal cells for cellular cardiomyoplasty: feasibility and potential clinical advantages. J Thorac Cardiovasc Surg 2000; 120:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/32\">",
"      Jain M, DerSimonian H, Brenner DA, et al. Cell therapy attenuates deleterious ventricular remodeling and improves cardiac performance after myocardial infarction. Circulation 2001; 103:1920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/33\">",
"      Ghostine S, Carrion C, Souza LC, et al. Long-term efficacy of myoblast transplantation on regional structure and function after myocardial infarction. Circulation 2002; 106:I131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/34\">",
"      Toma C, Pittenger MF, Cahill KS, et al. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002; 105:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/35\">",
"      Agbulut O, Vandervelde S, Al Attar N, et al. Comparison of human skeletal myoblasts and bone marrow-derived CD133+ progenitors for the repair of infarcted myocardium. J Am Coll Cardiol 2004; 44:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/36\">",
"      M&uuml;ller-Ehmsen J, Peterson KL, Kedes L, et al. Rebuilding a damaged heart: long-term survival of transplanted neonatal rat cardiomyocytes after myocardial infarction and effect on cardiac function. Circulation 2002; 105:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/37\">",
"      Hakuno D, Fukuda K, Makino S, et al. Bone marrow-derived regenerated cardiomyocytes (CMG Cells) express functional adrenergic and muscarinic receptors. Circulation 2002; 105:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/38\">",
"      Winter EM, Grauss RW, Hogers B, et al. Preservation of left ventricular function and attenuation of remodeling after transplantation of human epicardium-derived cells into the infarcted mouse heart. Circulation 2007; 116:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/39\">",
"      Nygren JM, Jovinge S, Breitbach M, et al. Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat Med 2004; 10:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/40\">",
"      Reinecke H, Poppa V, Murry CE. Skeletal muscle stem cells do not transdifferentiate into cardiomyocytes after cardiac grafting. J Mol Cell Cardiol 2002; 34:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/41\">",
"      Murry CE. Cardiac aid to the injured but not the elderly? Nat Med 2007; 13:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/42\">",
"      Bergmann O, Bhardwaj RD, Bernard S, et al. Evidence for cardiomyocyte renewal in humans. Science 2009; 324:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/43\">",
"      Bearzi C, Rota M, Hosoda T, et al. Human cardiac stem cells. Proc Natl Acad Sci U S A 2007; 104:14068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/44\">",
"      Oh H, Bradfute SB, Gallardo TD, et al. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci U S A 2003; 100:12313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/45\">",
"      Hsieh PC, Segers VF, Davis ME, et al. Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. Nat Med 2007; 13:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/46\">",
"      Kehat I, Kenyagin-Karsenti D, Snir M, et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest 2001; 108:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/47\">",
"      Xu C, Police S, Rao N, Carpenter MK. Characterization and enrichment of cardiomyocytes derived from human embryonic stem cells. Circ Res 2002; 91:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/48\">",
"      Laflamme MA, Gold J, Xu C, et al. Formation of human myocardium in the rat heart from human embryonic stem cells. Am J Pathol 2005; 167:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/49\">",
"      Melo LG, Pachori AS, Kong D, et al. Molecular and cell-based therapies for protection, rescue, and repair of ischemic myocardium: reasons for cautious optimism. Circulation 2004; 109:2386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/50\">",
"      Losordo DW, Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease: part II: cell-based therapies. Circulation 2004; 109:2692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/51\">",
"      Mathur A, Martin JF. Stem cells and repair of the heart. Lancet 2004; 364:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/52\">",
"      Wollert KC, Meyer GP, Lotz J, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004; 364:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/53\">",
"      Kang HJ, Kim HS, Zhang SY, et al. Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet 2004; 363:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/54\">",
"      Ince H, Petzsch M, Kleine HD, et al. Preservation from left ventricular remodeling by front-integrated revascularization and stem cell liberation in evolving acute myocardial infarction by use of granulocyte-colony-stimulating factor (FIRSTLINE-AMI). Circulation 2005; 112:3097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/55\">",
"      Strauer BE, Brehm M, Zeus T, et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002; 106:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/56\">",
"      Assmus B, Sch&auml;chinger V, Teupe C, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 2002; 106:3009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/57\">",
"      Britten MB, Abolmaali ND, Assmus B, et al. Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI): mechanistic insights from serial contrast-enhanced magnetic resonance imaging. Circulation 2003; 108:2212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/58\">",
"      Chen SL, Fang WW, Ye F, et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 2004; 94:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/59\">",
"      Janssens S, Dubois C, Bogaert J, et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 2006; 367:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/60\">",
"      Strauer BE, Brehm M, Zeus T, et al. Regeneration of human infarcted heart muscle by intracoronary autologous bone marrow cell transplantation in chronic coronary artery disease: the IACT Study. J Am Coll Cardiol 2005; 46:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/61\">",
"      Sch&auml;chinger V, Erbs S, Els&auml;sser A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006; 355:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/62\">",
"      Thum T, Bauersachs J, Poole-Wilson PA, et al. The dying stem cell hypothesis: immune modulation as a novel mechanism for progenitor cell therapy in cardiac muscle. J Am Coll Cardiol 2005; 46:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/63\">",
"      Meyer GP, Wollert KC, Lotz J, et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 2006; 113:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/64\">",
"      Erbs S, Linke A, Sch&auml;chinger V, et al. Restoration of microvascular function in the infarct-related artery by intracoronary transplantation of bone marrow progenitor cells in patients with acute myocardial infarction: the Doppler Substudy of the Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction (REPAIR-AMI) trial. Circulation 2007; 116:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/65\">",
"      Lunde K, Solheim S, Aakhus S, et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 2006; 355:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/66\">",
"      Zohlnh&ouml;fer D, Ott I, Mehilli J, et al. Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA 2006; 295:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/67\">",
"      Ripa RS, J&oslash;rgensen E, Wang Y, et al. Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: result of the double-blind, randomized, placebo-controlled stem cells in myocardial infarction (STEMMI) trial. Circulation 2006; 113:1983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/68\">",
"      Hill JM, Syed MA, Arai AE, et al. Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J Am Coll Cardiol 2005; 46:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/69\">",
"      Tse HF, Kwong YL, Chan JK, et al. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet 2003; 361:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/70\">",
"      Fuchs S, Satler LF, Kornowski R, et al. Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease: a feasibility study. J Am Coll Cardiol 2003; 41:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/71\">",
"      Perin EC, Dohmann HF, Borojevic R, et al. Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy. Circulation 2004; 110:II213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/72\">",
"      Perin EC, Dohmann HF, Borojevic R, et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 2003; 107:2294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/73\">",
"      Kloner RA. Attempts to recruit stem cells for repair of acute myocardial infarction: a dose of reality. JAMA 2006; 295:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/74\">",
"      Zbinden S, Zbinden R, Meier P, et al. Safety and efficacy of subcutaneous-only granulocyte-macrophage colony-stimulating factor for collateral growth promotion in patients with coronary artery disease. J Am Coll Cardiol 2005; 46:1636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/75\">",
"      Menasch&eacute; P, Hag&egrave;ge AA, Scorsin M, et al. Myoblast transplantation for heart failure. Lancet 2001; 357:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/76\">",
"      Hag&egrave;ge AA, Carrion C, Menasch&eacute; P, et al. Viability and differentiation of autologous skeletal myoblast grafts in ischaemic cardiomyopathy. Lancet 2003; 361:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/77\">",
"      Menasch&eacute; P, Hag&egrave;ge AA, Vilquin JT, et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol 2003; 41:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/78\">",
"      Dib N, Michler RE, Pagani FD, et al. Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy: four-year follow-up. Circulation 2005; 112:1748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/79\">",
"      Gavira JJ, Herreros J, Perez A, et al. Autologous skeletal myoblast transplantation in patients with nonacute myocardial infarction: 1-year follow-up. J Thorac Cardiovasc Surg 2006; 131:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/80\">",
"      Pagani FD, DerSimonian H, Zawadzka A, et al. Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans. Histological analysis of cell survival and differentiation. J Am Coll Cardiol 2003; 41:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/81\">",
"      Smits PC, van Geuns RJ, Poldermans D, et al. Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up. J Am Coll Cardiol 2003; 42:2063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/82\">",
"      Makkar RR, Lill M, Chen PS. Stem cell therapy for myocardial repair: is it arrhythmogenic? J Am Coll Cardiol 2003; 42:2070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/83\">",
"      Chang MG, Tung L, Sekar RB, et al. Proarrhythmic potential of mesenchymal stem cell transplantation revealed in an in vitro coculture model. Circulation 2006; 113:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/84\">",
"      Abraham MR, Henrikson CA, Tung L, et al. Antiarrhythmic engineering of skeletal myoblasts for cardiac transplantation. Circ Res 2005; 97:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/85\">",
"      Vulliet PR, Greeley M, Halloran SM, et al. Intra-coronary arterial injection of mesenchymal stromal cells and microinfarction in dogs. Lancet 2004; 363:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/86\">",
"      Breitbach M, Bostani T, Roell W, et al. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood 2007; 110:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18617/abstract/87\">",
"      Endo J, Sano M, Fujita J, et al. Bone marrow derived cells are involved in the pathogenesis of cardiac hypertrophy in response to pressure overload. Circulation 2007; 116:1176.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3470 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-197.136.42.3-C6403DFCA4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_11_18617=[""].join("\n");
var outline_f18_11_18617=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Sarcoplasmic reticulum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Beta adrenergic receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Adenylyl cyclase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      V2 vasopressin receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CELLULAR CARDIOMYOPLASTY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Organ transplantation as a model",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Mechanism of benefit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hematopoietic stem cell therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Acute MI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Ischemic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      G-CSF or GM-CSF alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Autologous skeletal myoblast transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Potential risks",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - In-stent restenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Perivascular fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16552?source=related_link\">",
"      Chapter 6B: Antidiuretic hormone and water balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39289?source=related_link\">",
"      Electrophysiologic cardiac mapping: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10632?source=related_link\">",
"      Excitation-contraction coupling in myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=related_link\">",
"      Genetics of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32455?source=related_link\">",
"      Pathophysiology of heart failure: Neurohumoral adaptations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_11_18618="Antithrombotic therapy in patients with prosthetic heart valves";
var content_f18_11_18618=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antithrombotic therapy in patients with prosthetic heart valves",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/11/18618/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/11/18618/contributors\">",
"     Gerard P Aurigemma, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/11/18618/contributors\">",
"     Barbara A Konkle, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/11/18618/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/11/18618/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/11/18618/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/11/18618/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/11/18618/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/11/18618/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/11/18618/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/11/18618/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients who undergo cardiac valve replacement, approximately 60 percent receive mechanical valves composed of carbon alloys with a tilting disk or bileaflet design. The remaining 40 percent receive bioprosthetic valves, which may be heterografts (primarily porcine or bovine tissue), homografts (preserved human aortic valves), or pulmonary autografts (",
"    <a class=\"graphic graphic_table graphicRef50825 \" href=\"UTD.htm?10/58/11181\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Replacement of a diseased heart valve with a prosthetic valve exchanges the native disease for potential prosthesis-related complications. The frequency of serious complications depends upon the valve type and position, and other clinical risk factors.",
"   </p>",
"   <p>",
"    Thromboembolic and anticoagulation-related problems are by far the most frequent complications of mechanical valves. In contrast, structural failure is relatively rare with these prostheses compared to bioprosthetic valves. Other major complications of prosthetic heart valves include endocarditis, paravalvular leak, and hemolysis. The complications as well as valve obstruction and valve thrombosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link\">",
"     \"Complications of prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are five main issues the clinician must face in managing the patient with a prosthetic heart valve:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Antithrombotic therapy to prevent valve thrombosis and thromboembolism",
"     </li>",
"     <li>",
"      Evaluation of valve function and durability",
"     </li>",
"     <li>",
"      Endocarditis prophylaxis",
"     </li>",
"     <li>",
"      Safety of exercise",
"     </li>",
"     <li>",
"      Pregnancy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review issues related to antithrombotic therapy and the cessation of such therapy for surgical procedures. Therapeutic use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , endocarditis prophylaxis, evaluation of valve function, the safety of exercise, and pregnancy in patients with prosthetic heart valves are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link\">",
"     \"Therapeutic use of warfarin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15238?source=see_link\">",
"     \"Management of patients with prosthetic heart valves\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1882?source=see_link\">",
"     \"Management of pregnant women with prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4298892\">",
"    <span class=\"h2\">",
"     Warfarin and aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    (or other vitamin K antagonist)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is recommended in patients with prosthetic heart valves to prevent valve thrombosis and thromboembolic events. The intensity of therapy varies with the type of valve (the risk is much greater with mechanical valves), the site of valve replacement (the risk is greater with mitral than aortic valves), the presence or absence of underlying risk factors for thrombus formation, and certain clinical settings, such as pregnancy and surgical procedures.",
"   </p>",
"   <p>",
"    An important concern with anticoagulation therapy is bleeding, particularly intracranial bleeding. These issues are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H28#H28\">",
"     \"Therapeutic use of warfarin\", section on 'Bleeding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=see_link\">",
"     \"Correcting excess anticoagulation after warfarin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10298?source=see_link\">",
"     \"Management of warfarin-associated intracerebral hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4298909\">",
"    <span class=\"h2\">",
"     Oral direct thrombin inhibitors and factor Xa inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newer oral antithrombotic agents include the direct thrombin inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    and the factor Xa inhibitors",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    . Dabigatran is not US FDA approved for use in patients with valvular heart disease and is specifically contraindicated in patients with mechanical heart valves [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/1\">",
"     1",
"    </a>",
"    ]. An FDA drug safety communication noted that the RE-ALIGN trial in patients with mechanical valves was stopped due to increased rates of stroke, myocardial infarction, and thrombosis in patients receiving dabigatran compared to those receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . Neither rivaroxaban nor apixaban have been studied in patients with prosthetic heart valves and are not approved for that indication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend against use of direct thrombin inhibitors such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    in patients with prosthetic heart valves. Patients with atrial fibrillation and bioprosthetic heart valves should be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , not direct thrombin inhibitors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANICAL VALVES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic embolization (predominantly cerebrovascular events) occurs at a frequency of approximately 0.7 to 1.0 percent per patient per year in patients with mechanical valves who are treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. In comparison, the risk is 2.2 percent per patient per year with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and 4.0 percent with no anticoagulation. Within this group, those with mitral valve prostheses are at approximately",
"    <strong>",
"     twice",
"    </strong>",
"    the risk compared to those with aortic valve prostheses [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initiation of anticoagulant therapy immediately after valve replacement requires careful monitoring. These patients are at risk for both thromboembolic complications and, since they are more sensitive to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    than nonsurgical patients, bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Possible mechanisms for increased sensitivity include a reduction in plasma albumin, a decrease in the binding capacity of warfarin, and the use of antibiotics after surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H28#H28\">",
"     \"Therapeutic use of warfarin\", section on 'Bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients often require measurement of the International Normalized Ratio (INR) two to three times per week as therapy is initiated. Once the patient is stable, the INR is assessed at least monthly, and the dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is adjusted as necessary. More frequent monitoring is required when the INR is outside the target range.",
"   </p>",
"   <p>",
"    A number of options are available for the outpatient management of anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . These include supervision by hospital-based or community-based physicians, anticoagulation clinics, and self-monitoring and self-management programs. Regardless of how this is accomplished, patients still spend a considerable period of time with their INR outside of the recommended range. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35880?source=see_link\">",
"     \"Outpatient management of oral anticoagulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Warfarin plus aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Support for the addition of antiplatelet therapy to anticoagulant therapy rather than anticoagulation alone in patients with mechanical valves comes from randomized trials. These results were summarized by two meta-analyses that each found that combined antiplatelet and anticoagulant therapy reduced the risk of mortality as well as the risk of thromboembolism as compared to anticoagulant therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The latter of these found moderate quality evidence that combined therapy versus anticoagulation alone significantly reduced the mortality rate (RR 0.58, 95% CI 0.40-0.86) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, the analysis found low quality evidence of significantly reduced thromboembolism (RR 0.42, 95% CI 0.21-0.81) and low quality evidence of increased risk of major hemorrhage (RR 1.44, 95% CI 1.0-2.08) with combined therapy versus anticoagulant only therapy.",
"   </p>",
"   <p>",
"    A transesophageal echocardiography study found that combined therapy reduced the incidence of nonobstructive thrombi as soon as nine days after placement of a mechanical mitral valve (5 versus 13 percent for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    alone) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mechanical valve recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (or other vitamin K antagonist, VKA) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (or other antiplatelet agent) in patients with mechanical heart valves have been published by three major societies: the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    in 2006 (",
"    <a class=\"graphic graphic_table graphicRef61063 \" href=\"UTD.htm?23/45/24284\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/10\">",
"     10",
"    </a>",
"    ], the Ninth American College of Chest Physicians (ACCP) guidelines on antithrombotic therapy in 2012 (",
"    <a class=\"graphic graphic_table graphicRef76851 \" href=\"UTD.htm?18/7/18556\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/7\">",
"     7",
"    </a>",
"    ], and the European Society of Cardiology (ESC) in 2012 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The three guidelines recommended that all patients with mechanical prosthetic valves be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (or other VKA) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/10,12,13\">",
"     10,12,13",
"    </a>",
"    ]. Although there were some differences in detail, all recommended that the intensity of warfarin therapy varies with the thrombogenicity of the valve, the presence or absence of other risk factors for thrombus formation (eg, atrial fibrillation, low left ventricular ejection fraction, prior thromboembolism),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the site of valve placement (aortic or mitral). Higher values of INR are associated with an increased risk of bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least five days of therapy is usually required for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    to achieve a therapeutic effect and it has been estimated that as many as one-third of patients leave the cardiac surgery unit before warfarin therapy is fully effective [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/6,15\">",
"     6,15",
"    </a>",
"    ]. Therefore, short-term bridging treatment with intravenous unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (IV UFH) or subcutaneous low molecular weight heparin (SQ LMWH) may be indicated. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Early anticoagulation post mechanical valve replacement'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    On the other hand, as noted above, some cardiac surgery patients are susceptible to excessively high INRs because of increased sensitivity to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H28#H28\">",
"     \"Therapeutic use of warfarin\", section on 'Bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possible indications for concurrent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in patients with mechanical heart valves are noted in the tables and include general indications for aspirin for the prevention of cardiovascular disease (",
"    <a class=\"graphic graphic_table graphicRef61063 \" href=\"UTD.htm?23/45/24284\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef76851 \" href=\"UTD.htm?18/7/18556\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef54908 \" href=\"UTD.htm?0/10/172\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are a number of relative contraindications to the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . These include [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History of gastrointestinal bleeding (eg, peptic ulcer disease, angiodysplasia).",
"     </li>",
"     <li>",
"      Poorly controlled hypertension, due to the risk of intracerebral hemorrhage .",
"     </li>",
"     <li>",
"      Patients with erratic anticoagulation control.",
"     </li>",
"     <li>",
"      Patients greater than 80 years of age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Early anticoagulation post mechanical valve replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a substantial risk of thromboembolic events immediately following mechanical valve replacement (particularly mitral) even when anticoagulation is initiated early post-operatively. In an observational study of patients who received intravenous unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    following mechanical valve replacement with early effective anticoagulation (by median day three for mitral and day four for aortic valve replacement), the rate of clinical thromboembolic events within 30 days was 0.7 percent for aortic valve replacement and 5 percent for mitral valve replacement (alone or combined with aortic valve replacement) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/16\">",
"     16",
"    </a>",
"    ]. Risk factors for thromboembolism included temporary cessation of anticoagulation for pacemaker implantation, heparin-induced thrombocytopenia, and diabetes mellitus.",
"   </p>",
"   <p>",
"    Following mechanical valve replacement as soon as the risk of post-operative bleeding is considered acceptable, we suggest treatment with UFH or LMWH until the INR is at therapeutic levels for two consecutive days. Evidence is limited to guide",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy in this early post-operative period and major society recommendations vary. The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    valvular guidelines recommended intravenous therapeutic dose unfractionated heparin (IV UFH) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/10\">",
"     10",
"    </a>",
"    ]. In the ESC guidelines, IV UFH or SQ LMWH is suggested, the latter with antifactor Xa monitoring to ensure therapeutic anticoagulation (",
"    <a class=\"graphic graphic_table graphicRef54908 \" href=\"UTD.htm?0/10/172\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/11\">",
"     11",
"    </a>",
"    ]. In contrast, the Ninth ACCP guidelines suggest either SQ prophylactic dose UFH or SQ prophylactic or therapeutic dose LMWH for post-valve replacement bridging (",
"    <a class=\"graphic graphic_table graphicRef76851 \" href=\"UTD.htm?18/7/18556\">",
"     table 3",
"    </a>",
"    ), given the results of observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the early post-operative period, there are few drawbacks of IV UFH because the patient is already hospitalized. However, there is frequent initial underdosing because of fear of bleeding. Therefore, there is interest in the use of SQ LMWH [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/6,15,17\">",
"     6,15,17",
"    </a>",
"    ]. However, concerns about SQ LMWH include: 1. the effect of SQ LMWH cannot be as easily reversed as that of IV UFH should bleeding develop and 2. fixed dose SQ LMWH may not ensure adequate anticoagulation in patients with mechanical valves, so monitoring of anti-factor Xa levels may be required [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     BIOPROSTHETIC VALVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major advantage of bioprosthetic valves is a low long-term rate of thromboembolism in the absence of risk factors, such as atrial fibrillation, a low LVEF, or a large left atrium. The reported rate of thromboembolic stroke has ranged from 0.2 to 3.3 percent per year in different studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/12,18\">",
"     12,18",
"    </a>",
"    ], but is only 0.7 percent per year in patients in sinus rhythm [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/10\">",
"     10",
"    </a>",
"    ]. The risk is greater with valves in the mitral compared to aortic position, where the risk may be as low as 0.2 percent in patients in sinus rhythm [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/12,19\">",
"     12,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Bioprosthetic valve long-term recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (or other vitamin K antagonist) therapy in patients with bioprosthetic valves were included in the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines (",
"    <a class=\"graphic graphic_table graphicRef75489 \" href=\"UTD.htm?6/5/6236\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/10\">",
"     10",
"    </a>",
"    ], the 2012 ACCP guidelines (",
"    <a class=\"graphic graphic_table graphicRef64047 \" href=\"UTD.htm?2/49/2844\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/7\">",
"     7",
"    </a>",
"    ], and the 2012 ESC guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is recommended in all patients with bioprosthetic valves unless a contraindication exists (dose 75 to 100",
"    <span class=\"nowrap\">",
"     mg/day;",
"    </span>",
"    except in patients with an indication for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    who are unable to take warfarin, in which case the dose is 75 to 325",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    Concurrent warfarin therapy is recommended in patients with risk factors for thromboembolism, including atrial fibrillation, prior thromboembolism, hypercoagulable condition, or severe left ventricular systolic dysfunction (ejection fraction &lt;0.30) (",
"    <a class=\"graphic graphic_table graphicRef75489 \" href=\"UTD.htm?6/5/6236\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. The goal INR in such patients with aortic or mitral bioprosthetic valves is 2.5 (range 2.0 to 3.0).",
"   </p>",
"   <p>",
"    In the 2012 ACCP guidelines,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is suggested after the first three months in patients in sinus rhythm with surgically implanted bioprosthetic valves (",
"    <a class=\"graphic graphic_table graphicRef64047 \" href=\"UTD.htm?2/49/2844\">",
"     table 6",
"    </a>",
"    ). As noted below, during the first three months, VKA therapy (target INR 2.5, range 2.0-3.0) is suggested in patients with a bioprosthetic mitral valve while aspirin therapy is suggested in patients in sinus rhythm (and without an indication for anticoagulation) with a bioprosthetic aortic valve. For the first three months after transcatheter aortic&nbsp;bioprosthetic valve implantation, aspirin (50 to 100",
"    <span class=\"nowrap\">",
"     mg/d)",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (75",
"    <span class=\"nowrap\">",
"     mg/d)",
"    </span>",
"    is suggested. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/29/34264?source=see_link&amp;anchor=H24148727#H24148727\">",
"     \"Transcatheter aortic valve replacement\", section on 'Antithrombotic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Initiation of anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with bioprosthetic valves for whom (early or indefinite)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy is indicated, intravenous unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (IV UFH) or subcutaneous low molecular weight heparin (SQ LMWH) is recommended until the INR is at therapeutic levels for two consecutive days. The ESC guideline favors IV UFH over SQ LMWH. If SQ LMWH is used, antifactor Xa monitoring is recommended to ensure therapeutic anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Early thromboembolic risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate issue is the role of anticoagulation to reduce the high thromboembolic risk during the first three months after bioprosthetic valve implantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Evidence of early risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an initial study from the Mayo Clinic, the risk was particularly high in the first 10 days following aortic or mitral bioprosthetic valve implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/18\">",
"     18",
"    </a>",
"    ]. Risk factors included lack of anticoagulation, mitral valve location, and prior thromboembolism.",
"   </p>",
"   <p>",
"    A later Mayo Clinic study examined ischemic stroke rates following mitral valve surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ischemic stroke rates in the first 30 days among patients who had undergone mitral valve repair (1.5 percent) or bioprosthetic (4.6 percent) or mechanical mitral valve replacement (1.3 percent) were greater than population expected rates despite routine anticoagulation. Early ischemic stroke rates were not significantly different among mitral procedure groups.",
"     </li>",
"     <li>",
"      Ischemic stroke risk in all groups decreased with time. After 180 days, ischemic stroke rate was similar to expected values in patients who had undergone mitral valve repair or bioprosthetic replacement. The risk of ischemic stroke was three to six times the expected rate among those undergoing mechanical valve replacement despite",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      anticoagulation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Early anticoagulation after bioprosthetic valve replacement or mitral valve repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of short-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for bioprosthetic valves in patients without thromboembolic risk factors or in patients with mitral valve annuloplasty is controversial. Limited data are available concerning the efficacy of warfarin therapy early after valve surgery.",
"   </p>",
"   <p>",
"    Two small unblinded randomized trials comparing early VKA with antiplatelet agent in patients receiving aortic bioprosthetic valves did not find significant differences in outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An observational study examined data from the Danish National Patient Registry on 4075 patients without atrial fibrillation receiving a bioprosthetic aortic valve [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/23\">",
"     23",
"    </a>",
"    ]. The study population included 3186 patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , 881 not on warfarin, and eight patients who were excluded who discontinued warfarin within 30 days. Stroke was significantly more frequent during 30 to 89 days following surgery in patients who had discontinued warfarin. Thromboembolic events were significantly more frequent during 30 to 89 days and 90 to 179 days in patients who had discontinued warfarin. Cardiovascular death was significantly more frequent during 30 to 89 days, 90 to 179 days, and 180 to 364 days in the patients who had discontinued warfarin. Of note, bleeding incidents were more frequent during 30 to 89 days in patients who had discontinued warfarin but after one year bleeding was more frequent in patients who continued warfarin treatment. In summary, this registry study of patients receiving bioprosthetic aortic valves found an association between discontinuation of warfarin within six months after surgery and thromboembolic events and cardiovascular death but a causal relationship was not established. &nbsp;",
"   </p>",
"   <p>",
"    Given the available evidence, the role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy during the first few months after bioprosthetic valve placement (in patients without other indications for anticoagulation) is uncertain.",
"   </p>",
"   <p>",
"    Major society guidelines provide differing recommendations. The 2012 ESC guidelines indicate that oral anticoagulation should be considered for the first three months after mitral or tricuspid bioprosthesis placement and may be considered in the first three months following aortic bioprosthetic valve replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/11\">",
"     11",
"    </a>",
"    ]. The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines with 2008 focused update considered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy (goal INR 2.0 to 3.0) to be useful in the first three months after aortic or mitral valve bioprosthetic valve implantation in patients with no risk factors (",
"    <a class=\"graphic graphic_table graphicRef75489 \" href=\"UTD.htm?6/5/6236\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2012 ACCP guidelines for bioprosthetic valve surgery in patients without thromboembolic risk factors recommended",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    during the first three months only for patients with mitral valve replacement (",
"    <a class=\"graphic graphic_table graphicRef64047 \" href=\"UTD.htm?2/49/2844\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2835682\">",
"    <span class=\"h1\">",
"     VALVE REPAIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited evidence is available to guide antithrombotic therapy following mitral or aortic valve repair and major society guidelines provide differing recommendations.",
"   </p>",
"   <p>",
"    The 2005 ESC guidelines recommended",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (or other VKA) (goal INR 2.0 to 3.0) in the first three months following mitral valve repair with prosthetic annuloplasty ring [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/13\">",
"     13",
"    </a>",
"    ]. The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines with 2008 focused update considered such an approach reasonable (a weaker recommendation) following mitral valve repair [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ACCP guidelines suggested the use of antiplatelet therapy for the first three months following mitral valve repair instead of VKA therapy (",
"    <a class=\"graphic graphic_table graphicRef64047 \" href=\"UTD.htm?2/49/2844\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/7\">",
"     7",
"    </a>",
"    ]. This suggestion was based upon data from an observational study suggesting the superiority of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in preventing thromboembolism after mitral repair or bioprosthetic valve replacement; however, the majority of the patients in this study underwent bioprosthetic valve replacement rather than valve repair [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/24\">",
"     24",
"    </a>",
"    ]. Based upon observational data [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/25,26\">",
"     25,26",
"    </a>",
"    ], the ACCP guidelines suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (50 to 100",
"    <span class=\"nowrap\">",
"     mg/d)",
"    </span>",
"    instead of VKA therapy for patients who have undergone aortic valve repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SPECIAL CIRCUMSTANCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In managing antithrombotic therapy in patients with prosthetic heart valves, there are special circumstances (pregnancy and elderly adults) and additional issues (thromboembolism despite antithrombotic therapy, correction of over-anticoagulation, and discontinuing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for surgical procedures) that require attention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with mechanical prosthetic heart valves have a heightened risk of thromboembolic events during pregnancy. Anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    provides protection against these complications, but increases the risk of embryopathy. Thus, the approach to the prevention of thromboembolism in pregnant women with prosthetic heart valves differs from that in nonpregnant patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1882?source=see_link\">",
"     \"Management of pregnant women with prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of bioprosthetic valves in elderly adults is well established. With aortic valves, the rate of structural deterioration is much lower in patients over age 70 (actuarial rate 10 percent at 15 years) due at least in part to decreased activity in older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/27\">",
"     27",
"    </a>",
"    ]. In comparison, the use of mechanical valves has been controversial, largely related to an increased risk of bleeding associated with anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. However, some elderly patients do well with mechanical valves [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/36/34377?source=see_link&amp;anchor=H5#H5\">",
"     \"Valvular heart disease in elderly adults\", section on 'Choice of aortic valve prosthesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/14/1258?source=see_link\">",
"     \"Anticoagulation in older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Thromboembolism despite antithrombotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above recommendations for antithrombotic therapy in patients with mechanical or bioprosthetic heart valves reduce but do not eliminate thromboembolic events. Randomized trial data are not available on the optimal approach for patients who develop thromboembolic events on standard therapy.",
"   </p>",
"   <p>",
"    This issue was most completely addressed in the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines, which recommended the following approach to increasing the intensity of therapy when it can be safely performed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with a goal INR of 2.0 to 3.0 &mdash; increase the goal INR to 2.5 to 3.5",
"     </li>",
"     <li>",
"      Among patients with a goal INR of 2.5 to 3.5 &mdash; the goal INR may need to be increased to 3.5 to 4.5",
"     </li>",
"     <li>",
"      Among patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (75 to 100",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      &mdash; if the higher dose of warfarin does not prevent further thromboembolic events, the aspirin dose may need to be increased to 325",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"     <li>",
"      Among patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      but not",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      &mdash; add aspirin (75 to 100",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"     </li>",
"     <li>",
"      Among patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      alone &mdash; the aspirin dose may need to be increased to 325",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      added (75",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      added",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In comparison, the 2012 ESC guidelines made more limited recommendations. The ESC guidelines recommended that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    be added to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy only after treatment of identified risk factors and a full evaluation and optimization of warfarin therapy have proven unsuccessful [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Valve thrombosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link\">",
"     \"Complications of prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     BLEEDING AND CORRECTION OF OVERANTICOAGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of major bleeding with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    begins to rise steeply when the INR increases to values &ge;5.0 (",
"    <a class=\"graphic graphic_figure graphicRef65373 \" href=\"UTD.htm?42/18/43296\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/31\">",
"     31",
"    </a>",
"    ]. General issues related to overanticoagulation with warfarin, including the 2012 ACCP guidelines, are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=see_link&amp;anchor=H6#H6\">",
"     \"Correcting excess anticoagulation after warfarin\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of overanticoagulation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bleeding is complicated in patients with prosthetic heart valves because overcorrection carries a risk of valve thrombosis. Because of these concerns, the 2012 ESC guideline recommendations vary with the clinical setting [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who are not bleeding and have an INR &ge;6.0,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      should be temporarily discontinued to permit a gradual reduction in INR; small doses (1 or 2 mg) of oral vitamin K may be administered to help hasten the fall in INR. Intravenous vitamin K should",
"      <strong>",
"       not",
"      </strong>",
"      be given because of the risk of valve thrombosis if the INR falls too quickly.",
"     </li>",
"     <li>",
"      If the INR is &gt;10 and there is no bleeding,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      should be discontinued and doses of 2 to 5 mg of",
"      <strong>",
"       oral",
"      </strong>",
"      vitamin K should be administered.",
"      <br/>",
"      <br/>",
"      The 2006",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      guidelines and others note that, in contrast to the risk of high-dose intravenous vitamin K, low-dose (1 to 2.5 mg)",
"      <strong>",
"       oral",
"      </strong>",
"      vitamin K safely corrects the excessive degree of anticoagulation more rapidly than simple withholding of warfarin, without making the patient temporarily resistant to further therapy with warfarin [",
"      <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=see_link&amp;anchor=H13#H13\">",
"       \"Correcting excess anticoagulation after warfarin\", section on 'INR &gt;9 without bleeding'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bleeding in patients who are therapeutically anticoagulated or over-anticoagulated often comes from a pathologic cause that should be identified and treated.",
"     </li>",
"     <li>",
"      In patients who are bleeding with a therapeutic or high INR, the risk of major bleeding (eg, not amenable to local control and life threatening [eg, intracranial] or causing hemodynamic instability) must be weighed against the risk of valve thrombosis. High-risk features for thromboembolism are described below. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Patients with high thromboembolic risk'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      When major bleeding occurs, immediate reversal of anticoagulation is recommended using intravenous prothrombin complex concentrate (PCC) combined with oral vitamin K. PCC, when available, is preferred over fresh frozen plasma (FFP). The INR should be monitored frequently. Doses of oral vitamin K may be repeated at 12-hour intervals, if needed. PCC can be repeated if necessary, depending upon the INR response. Recombinant activated factor VII is",
"      <strong>",
"       not",
"      </strong>",
"      recommended for reversal because of evidence of lack of efficacy and concern for risk of thrombosis, especially in the elderly [",
"      <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. A study in normal controls given",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      demonstrated correction of the INR and other coagulation tests with rFVIIa but no decrease in bleeding in a skin punch biopsy model [",
"      <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/33\">",
"       33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=see_link&amp;anchor=H15#H15\">",
"       \"Correcting excess anticoagulation after warfarin\", section on 'Significant or life-threatening bleeding'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Among PCC products available in the United States (but not those available in Canada and Europe), the so-called \"three-factor\" PCCs, may have low concentrations of factor VII, requiring additional use of FFP to effectively lower an elevated INR [",
"      <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/34\">",
"       34",
"      </a>",
"      ]. However, &ldquo;four-factor&rdquo; products are under study in the US and one product is under review by the FDA. &nbsp;",
"     </li>",
"     <li>",
"      The optimal time to resume",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy after a major bleeding episode is uncertain. Considerations include the site and cause of the bleeding and interventions performed to stop the bleeding or treat its cause. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H1230806#H1230806\">",
"       \"Therapeutic use of warfarin\", section on 'Resumption of warfarin after bleeding'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     INTERRUPTION OF WARFARIN FOR SURGICAL PROCEDURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     General considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients on long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy may require reversal of warfarin anticoagulation, most often to prevent bleeding at the time of elective surgery. Less often, reversal of anticoagulation is required for emergent surgery or other urgent indications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link\">",
"     \"Management of anticoagulation before and after elective surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21014?source=see_link\">",
"     \"Management of anticoagulants in patients undergoing endoscopic procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of thromboembolism is particularly high early after mechanical or bioprosthetic mitral replacement or mitral valve repair, so one potential method to reduce thromboembolic risk is to wait at least three months after valve surgery for elective noncardiac surgery, when feasible. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Early anticoagulation post mechanical valve replacement'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H11\">",
"     'Early thromboembolic risk'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The optimal approach to anticoagulation at the time of noncardiac surgery in patients with mechanical heart valves is uncertain. Much of the available data are from small, uncontrolled case series that often include patients with older generation prosthetic valves. In these reports, thromboembolic risk was variable, depending upon the type and location of the valve prosthesis and upon a number of patient-specific clinical factors.",
"   </p>",
"   <p>",
"    In an individual patient, the thromboembolic risk must be balanced against the bleeding risk, which largely depends upon the nature and urgency of the surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/35\">",
"     35",
"    </a>",
"    ]. Most patients tolerate short-term interruption of anticoagulation without valve thrombosis or thromboembolism. This was illustrated in a report of 159 patients who underwent a total of 180 noncardiac operations with mitral or combined mechanical valves [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/36\">",
"     36",
"    </a>",
"    ]. Oral anticoagulants were discontinued one to three days preoperatively and for one to seven days after surgery. There were no perioperative thromboembolic events.",
"   </p>",
"   <p>",
"    Although the risk appears to be low in most patients, most cases of valve thrombosis (70 percent in one series) occur during periods of inadequate anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link&amp;anchor=H9#H9\">",
"     \"Complications of prosthetic heart valves\", section on 'Valve thrombosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with mechanical valves who require interruption of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy for surgery, invasive procedures, or dental care, high dose vitamin K should NOT be routinely administered since this will significantly delay the ability to re-anticoagulate with warfarin [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/10\">",
"     10",
"    </a>",
"    ]. In contrast, if the INR is &ge;1.5 on the day prior to surgery, it is reasonable to administer a low dose (eg, 1.0 to 2.5 mg) of oral vitamin K as discussed below. (See",
"    <a class=\"local\" href=\"#H2836061\">",
"     'Standardized perioperative procedure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2836061\">",
"    <span class=\"h3\">",
"     Standardized perioperative procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;As suggested in the 2012 ACCP guidelines, a standardized procedure for perioperative anticoagulant therapy may aid efficient patient management [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/38\">",
"     38",
"    </a>",
"    ]. Components may include advance planning of perioperative anticoagulant management (at least seven days before the procedure, especially before major surgery), providing patients and providers with a calendar outlining the timing of INR testing, anticoagulant discontinuation and resumption, bridging therapy, providing education on injection technique for any outpatient LMWH therapy, and assessment of post-operative hemostasis. INR testing on the day before surgery enables timely use of oral vitamin K to reduce the need for blood products or deferral of the surgical procedure. If the INR is 1.5 to 1.9 on the day before surgery, administration of a low dose of oral vitamin K (eg, 1.0 to 2.5 mg) is likely to reduce the INR to 1.4 or less on the day of surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Role of bridging anticoagulation with heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;When",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is discontinued in preparation for a procedure, assessment of the need for bridging",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    anticoagulation when warfarin is discontinued is based upon patient and prosthesis specific risk factors for thromboembolism.",
"   </p>",
"   <p>",
"    Limited data are available on the efficacy of bridging therapy. A small series demonstrated the potential value of basing the approach upon the location of the mechanical prosthetic valve [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/40\">",
"     40",
"    </a>",
"    ]. In 16 operations on patients with only an aortic prosthesis, oral anticoagulation was discontinued for three to five days without intravenous unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (IV UFH) coverage. In 26 operations on patients with mechanical mitral prostheses, the patients were treated with IV UFH during the period when oral anticoagulation was discontinued; IV UFH was interrupted only for 12 hours at the time of surgery. There were no thromboembolic events in either group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Major guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    valvular disease guidelines (with 2008 focused update), the 2005 ESC statement, the 2007 ESC valvular guidelines and the 2012 ACCP guidelines included recommendations for the perioperative management of anticoagulation in patients with prosthetic heart valves that emphasized the importance of patient-specific thromboembolic risk and procedure-specific bleeding risk [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/10,11,38\">",
"     10,11,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In these guidelines, perioperative management when anticoagulation interruption is deemed necessary is determined by patient-specific thromboembolic risk (",
"    <a class=\"graphic graphic_table graphicRef56682 \" href=\"UTD.htm?40/44/41676\">",
"     table 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef56916 \" href=\"UTD.htm?23/32/24076\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/10-12,38\">",
"     10-12,38",
"    </a>",
"    ]. Bridging anticoagulation is recommended for patients at high risk for thromboembolism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Choice of heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (IV UFH) or subcutaneous low molecular weight heparin (SQ LMWH) may be used for bridging anticoagulation (",
"    <a class=\"graphic graphic_table graphicRef56682 \" href=\"UTD.htm?40/44/41676\">",
"     table 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef56916 \" href=\"UTD.htm?23/32/24076\">",
"     table 8",
"    </a>",
"    ). Compared to IV UFH, SQ LMWH is more convenient to use and may result in a more predictable degree of anticoagulation. When used as a \"bridging\" therapy in patients with mechanical valve prostheses, LMWH may be more cost effective than unfractionated heparin [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/34,41\">",
"     34,41",
"    </a>",
"    ]. A potential concern is that, if severe bleeding occurs, the effect of LMWH cannot be as easily reversed as that of unfractionated heparin [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given these competing concerns, major society guidelines offer differing recommendations on choice of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . The",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    and ESC guidelines favor use of IV UFH over SC LMWH in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The 2012 ACCP guidelines discuss use of IV UFH or therapeutic-dose SC LMWH [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our recommendations are in general agreement with those of the major society guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Patients with high thromboembolic risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    and 2012 ESC guidelines identified features associated with high risk for thromboembolism (",
"    <a class=\"graphic graphic_table graphicRef56682 \" href=\"UTD.htm?40/44/41676\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The 2012 ACCP guidelines suggest stratification into high, moderate, and low risk of thromboembolism categories [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend the following risk stratification based upon a composite of these guidelines. Presence of any one of the following features is associated with high risk:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrial fibrillation, prior thromboembolism, severe left ventricular systolic dysfunction (EF &lt;30 percent), or the presence of a hypercoagulable state.",
"     </li>",
"     <li>",
"      Patients with a mechanical mitral or tricuspid valve, two or more mechanical valves, or older aortic caged-ball or tilting disc valves (eg, Lillehei Kaster, Omniscience, Starr Edwards). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanical valves'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgery for malignancy or infection, which is associated with hypercoagulability.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For minor surgery in high-risk patients (eg, minor dermatologic procedures or cataract surgery), we suggest continuing the oral anticoagulant if possible [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/38\">",
"     38",
"    </a>",
"    ]. For a minor dental procedure (eg, tooth extraction or endodontal [root canal] procedure) we suggest continuing the oral anticoagulant with coadministration of an oral prohemostatic agent (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    4.8 percent administered off-label as an oral rinse of 5 mL taken 5 to 10 minutes before the dental procedure and three to four times daily for one to two days after the procedure). An alternative approach for minor dental procedures is to stop oral anticoagulant therapy for two to three days before the procedure (which is expected to result in an INR of 1.6 to 1.9 on the day of the procedure.)",
"   </p>",
"   <p>",
"    For more extensive surgery, we suggest the following approach if interruption of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy is considered essential in a high-risk patient:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Discontinue",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      five days prior to surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Initiate intravenous unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (IV UFH) when the INR falls below the target range. The dose of IV UFH is adjusted to achieve an activated PTT that is 1.5 to 2.0 times control [",
"      <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Therapeutic-dose (weight-based) subcutaneous LMWH (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      100",
"      <span class=\"nowrap\">",
"       IU/kg",
"      </span>",
"      [equivalent to 1",
"      <span class=\"nowrap\">",
"       mg/kg]",
"      </span>",
"      every 12 hours) may be used in place of intravenous unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , although guideline recommendations have varied. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Choice of heparin'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We suggest against routine use of anti-factor Xa for monitoring therapy if therapeutic-dose SQ LMWH therapy is used for bridging therapy in nonpregnant patients. However, in pregnant women with prosthetic heart valves treated with SQ LMWH, monitoring is essential (ie, \"adjusted dose\" rather than \"therapeutic dose\" LMWH) and a high anti-Xa level is recommended. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1882?source=see_link\">",
"       \"Management of pregnant women with prosthetic heart valves\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      IV UFH should be discontinued four to six hours before the procedure, while SQ LMWH should be discontinued 24 hours prior to the procedure. For the last preoperative dose of LMWH, administration of half the total daily dose (rather than 100 percent of the total daily dose) is recommended [",
"      <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IV UFH or SQ LMWH should be restarted as soon as possible after surgery considering both the risk for bleeding and the adequacy of surgical hemostasis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Following a minor surgical or other invasive procedure when adequate hemostasis has been achieved, resumption of therapeutic dose SQ LMWH is suggested after approximately 24 hours.",
"     </li>",
"     <li>",
"      Following major surgery or a high bleeding risk surgery or procedure, resumption of therapeutic dose LMWH or UFH 48 to 72 hours surgery when hemostasis is secure OR completely avoiding LMWH or UFH after surgery is suggested rather than earlier administration of therapeutic dose LMWH or UFH. The individual anticipated bleeding risk and adequacy of postoperative hemostasis should be considered in determining the timing of LMWH or UFH resumption.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      should be reinstituted as soon as possible after surgery (eg, 12 to 24 h after surgery and when there is adequate hemostasis) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/38\">",
"       38",
"      </a>",
"      ]. IV UFH or SQ LMWH should be discontinued once the INR is in the therapeutic range for two consecutive days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Patients with low thromboembolic risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients without the risk factors described in the previous section are considered at low thromboembolic risk. We suggest the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Minor surgery &mdash; In preparation for minor procedures such as skin biopsy or dental extractions, it is important to confirm that the INR does not exceed the therapeutic range. Although",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy can be continued in most patients, we withhold warfarin for two days prior to the procedure in low-risk patients, and reinstitute therapy after the procedure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link\">",
"       \"Management of anticoagulation before and after elective surgery\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21014?source=see_link\">",
"       \"Management of anticoagulants in patients undergoing endoscopic procedures\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Major surgery &mdash; Among patients with a mechanical aortic valve prosthesis and no other risk factors for thromboembolism, we suggest discontinuing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy five days before surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/38\">",
"       38",
"      </a>",
"      ]. No bridging anticoagulation is usually necessary. After a normal INR is confirmed, surgery is performed. Warfarin anticoagulation is reinstituted as soon as possible after surgery (eg, 12 to 24 h after surgery and when there is adequate hemostasis) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/38\">",
"       38",
"      </a>",
"      ], because it will take a few days for the INR to reach a therapeutic level.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     INTERRUPTION OF WARFARIN FOR CARDIAC CATHETERIZATION/ANGIOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate issue from discontinuing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for surgery is the management of patients with prosthetic heart valves being treated with antithrombotic therapy who require cardiac",
"    <span class=\"nowrap\">",
"     catheterization/angiography.",
"    </span>",
"    The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines proposed the following general approach [",
"    <a class=\"abstract\" href=\"UTD.htm?18/11/18618/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is preferable to discontinue",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      for approximately 72 hours before the procedure to allow the INR to fall below 1.5 (or below 1.2 if transseptal or left ventricular puncture is planned). However, urgent or semiurgent cardiac catheterization can be performed in patients taking warfarin.",
"     </li>",
"     <li>",
"      When",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      is discontinued, it should be restarted as soon as the procedure is completed.",
"     </li>",
"     <li>",
"      Among patients with more than one risk factor for thromboembolism, intravenous unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (IV UFH) should be started as soon as the INR falls below 2.0 and continued when",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      is reinstituted. IV UFH can be discontinued once the INR is in the therapeutic range for two consecutive days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (LMWH) is",
"    <strong>",
"     not",
"    </strong>",
"    recommended in patients undergoing cardiac catheterization because of its long half-life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/23/11635?source=see_link\">",
"       \"Patient information: Prosthetic valves (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=see_link\">",
"       \"Patient information: Warfarin (Coumadin) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21687972\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thromboembolic and anticoagulation-related problems are by far the most frequent complications of mechanical valves. In contrast, structural failure is relatively rare with these prostheses compared to bioprosthetic valves.",
"     </li>",
"     <li>",
"      Systemic embolization (predominantly cerebrovascular events) occurs at a frequency of approximately 0.7 to 1.0 percent per patient per year in patients with mechanical valves who are treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      . In comparison, the risk is 2.2 percent per patient per year with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and 4.0 percent with no anticoagulation. Patients with mitral valve prostheses are at approximately",
"      <strong>",
"       twice",
"      </strong>",
"      the risk compared to those with aortic valve prostheses. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Warfarin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with mechanical prosthetic valves, we recommend long-term treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      (or other VKA) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      75 to 100",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Mechanical valve recommendations'",
"      </a>",
"      above.) The goal INR varies with valve position and type (",
"      <a class=\"graphic graphic_table graphicRef61063 \" href=\"UTD.htm?23/45/24284\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef76851 \" href=\"UTD.htm?18/7/18556\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef54908 \" href=\"UTD.htm?0/10/172\">",
"       table 4",
"      </a>",
"      ). Recommendations for anticoagulation during pregnancy are discussed separately (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1882?source=see_link\">",
"       \"Management of pregnant women with prosthetic heart valves\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The risk of thromboembolic events immediately following mechanical valve replacement (particularly mitral) is substantial even when anticoagulation is initiated early postoperatively. Following mechanical valve replacement as soon as the risk of postoperative bleeding is considered acceptable, we suggest intravenous unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (IV UFH) or subcutaneous low molecular weight heparin (LMWH) continuing until the INR is at therapeutic levels for two consecutive days. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Early anticoagulation post mechanical valve replacement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The oral direct thrombin inhibitor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      and the factor Xa inhibitors",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/62/39911?source=see_link\">",
"       apixaban",
"      </a>",
"      should NOT be considered alternatives to therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      and we do NOT recommend their use in patients with prosthetic heart valves.",
"     </li>",
"     <li>",
"      For patients with bioprosthetic valves we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      75 to 100",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (except in patients with an indication for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      who are unable to take warfarin, in which case the dose is 75 to 325",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      <br/>",
"      <br/>",
"      Concurrent warfarin therapy is recommended in patients with risk factors for thromboembolism, including atrial fibrillation, prior thromboembolism, hypercoagulable condition, or severe left ventricular systolic dysfunction (ejection fraction &lt;0.30) (",
"      <a class=\"graphic graphic_table graphicRef75489 \" href=\"UTD.htm?6/5/6236\">",
"       table 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef64047 \" href=\"UTD.htm?2/49/2844\">",
"       table 6",
"      </a>",
"      ). The goal INR in such patients with aortic or mitral bioprosthetic valves is 2.5 (range 2.0 to 3.0). Patients with atrial fibrillation and bioprosthetic heart valves should be treated with warfarin, not direct thrombin inhibitors. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Bioprosthetic valve long-term recommendations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients who are not bleeding, those with an INR &ge;6.0 should be admitted to the hospital and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      should be temporarily discontinued to permit a gradual reduction in INR. Intravenous vitamin K should",
"      <strong>",
"       not",
"      </strong>",
"      be given because of the risk of valve thrombosis if the INR falls too quickly. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Bleeding and correction of overanticoagulation'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      If the INR is &gt;9 without bleeding, warfarin should be discontinued and 1 to 2.5 mg of",
"      <strong>",
"       oral",
"      </strong>",
"      vitamin K should be administered.",
"     </li>",
"     <li>",
"      In patients who are bleeding with a therapeutic or high INR, the risk from major bleeding (eg, intracranial) must be weighed against the risk of valve thrombosis. If the risk from continued bleeding that is inaccessible to local control (particularly intracerebral bleeding) is considered greater than the risk of valve thrombosis, cessation of anticoagulation should be accomplished by the use of fresh frozen plasma (FFP) or 2.5 to 5.0 mg of intravenous vitamin K. For urgent situations, prothrombin complex concentrate (PCC) may be employed. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Bleeding and correction of overanticoagulation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=see_link&amp;anchor=H15#H15\">",
"       \"Correcting excess anticoagulation after warfarin\", section on 'Significant or life-threatening bleeding'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      is discontinued in preparation for a procedure, assessment of the need for bridging",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      anticoagulation when warfarin is discontinued is based upon patient and prosthesis-specific risk factors for thromboembolism (",
"      <a class=\"graphic graphic_table graphicRef56682 \" href=\"UTD.htm?40/44/41676\">",
"       table 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef56916 \" href=\"UTD.htm?23/32/24076\">",
"       table 8",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Major guidelines'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Our approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm332949.htm?source=govdelivery (Accessed on December 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/2\">",
"      Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/3\">",
"      Cannegieter SC, Rosendaal FR, Bri&euml;t E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994; 89:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/4\">",
"      Kontozis L, Skudicky D, Hopley MJ, Sareli P. Long-term follow-up of St. Jude Medical prosthesis in a young rheumatic population using low-level warfarin anticoagulation: an analysis of the temporal distribution of causes of death. Am J Cardiol 1998; 81:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/5\">",
"      Ageno W, Turpie AG. Exaggerated initial response to warfarin following heart valve replacement. Am J Cardiol 1999; 84:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/6\">",
"      Goldhaber SZ. \"Bridging\" and mechanical heart valves: perils, promises, and predictions. Circulation 2006; 113:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/7\">",
"      Whitlock RP, Sun JC, Fremes SE, et al. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e576S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/8\">",
"      Little SH, Massel DR. Antiplatelet and anticoagulation for patients with prosthetic heart valves. Cochrane Database Syst Rev 2003; :CD003464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/9\">",
"      Laffort P, Roudaut R, Roques X, et al. Early and long-term (one-year) effects of the association of aspirin and oral anticoagulant on thrombi and morbidity after replacement of the mitral valve with the St. Jude medical prosthesis: a clinical and transesophageal echocardiographic study. J Am Coll Cardiol 2000; 35:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/10\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/11\">",
"      Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC), European Association for Cardio-Thoracic Surgery (EACTS), Vahanian A, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012; 33:2451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/12\">",
"      Salem DN, O'Gara PT, Madias C, et al. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:593S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/13\">",
"      Butchart EG, Gohlke-B&auml;rwolf C, Antunes MJ, et al. Recommendations for the management of patients after heart valve surgery. Eur Heart J 2005; 26:2463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/14\">",
"      Torn M, van der Meer FJ, Rosendaal FR. Lowering the intensity of oral anticoagulant therapy: effects on the risk of hemorrhage and thromboembolism. Arch Intern Med 2004; 164:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/15\">",
"      Meurin P, Tabet JY, Weber H, et al. Low-molecular-weight heparin as a bridging anticoagulant early after mechanical heart valve replacement. Circulation 2006; 113:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/16\">",
"      Allou N, Piednoir P, Berro&euml;ta C, et al. Incidence and risk factors of early thromboembolic events after mechanical heart valve replacement in patients treated with intravenous unfractionated heparin. Heart 2009; 95:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/17\">",
"      Fanikos J, Tsilimingras K, Kucher N, et al. Comparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation. Am J Cardiol 2004; 93:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/18\">",
"      Heras M, Chesebro JH, Fuster V, et al. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol 1995; 25:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/19\">",
"      Cohn LH, Mudge GH, Pratter F, Collins JJ Jr. Five to eight-year follow-up of patients undergoing porcine heart-valve replacement. N Engl J Med 1981; 304:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/20\">",
"      Russo A, Grigioni F, Avierinos JF, et al. Thromboembolic complications after surgical correction of mitral regurgitation incidence, predictors, and clinical implications. J Am Coll Cardiol 2008; 51:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/21\">",
"      Aramendi JI, Mestres CA, Mestres CA, et al. Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (trac): prospective, randomized, co-operative trial. Eur J Cardiothorac Surg 2005; 27:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/22\">",
"      Colli A, Mestres CA, Castella M, Gherli T. Comparing warfarin to aspirin (WoA) after aortic valve replacement with the St. Jude Medical Epic heart valve bioprosthesis: results of the WoA Epic pilot trial. J Heart Valve Dis 2007; 16:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/23\">",
"      M&eacute;rie C, K&oslash;ber L, Skov Olsen P, et al. Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. JAMA 2012; 308:2118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/24\">",
"      Aramendi JL, Agredo J, Llorente A, et al. Prevention of thromboembolism with ticlopidine shortly after valve repair or replacement with a bioprosthesis. J Heart Valve Dis 1998; 7:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/25\">",
"      Duran CM, Gometza B, Kumar N, et al. From aortic cusp extension to valve replacement with stentless pericardium. Ann Thorac Surg 1995; 60:S428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/26\">",
"      Duran CM, Gometza B, Shahid M, Al-Halees Z. Treated bovine and autologous pericardium for aortic valve reconstruction. Ann Thorac Surg 1998; 66:S166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/27\">",
"      Yun KL, Miller DC, Moore KA, et al. Durability of the Hancock MO bioprosthesis compared with standard aortic valve bioprostheses. Ann Thorac Surg 1995; 60:S221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/28\">",
"      Levine MN, Raskob G, Hirsh J. Hemorrhagic complications of long-term anticoagulant therapy. Chest 1989; 95:26S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/29\">",
"      Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/30\">",
"      Masters RG, Semelhago LC, Pipe AL, Keon WJ. Are older patients with mechanical heart valves at increased risk? Ann Thorac Surg 1999; 68:2169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/31\">",
"      Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/32\">",
"      Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/33\">",
"      Skolnick BE, Mathews DR, Khutoryansky NM, et al. Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects. Blood 2010; 116:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/34\">",
"      Amorosi SL, Tsilimingras K, Thompson D, et al. Cost analysis of \"bridging therapy\" with low-molecular-weight heparin versus unfractionated heparin during temporary interruption of chronic anticoagulation. Am J Cardiol 2004; 93:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/35\">",
"      Katholi RE, Nolan SP, McGuire LB. Living with prosthetic heart valves. Subsequent noncardiac operations and the risk of thromboembolism or hemorrhage. Am Heart J 1976; 92:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/36\">",
"      Tinker JH, Tarhan S. Discontinuing anticoagulant therapy in surgical patients with cardiac valve prostheses. Observations in 180 operations. JAMA 1978; 239:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/37\">",
"      Deviri E, Sareli P, Wisenbaugh T, Cronje SL. Obstruction of mechanical heart valve prostheses: clinical aspects and surgical management. J Am Coll Cardiol 1991; 17:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/38\">",
"      Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e326S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/39\">",
"      Woods K, Douketis JD, Kathirgamanathan K, et al. Low-dose oral vitamin K to normalize the international normalized ratio prior to surgery in patients who require temporary interruption of warfarin. J Thromb Thrombolysis 2007; 24:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/40\">",
"      Katholi RE, Nolan SP, McGuire LB. The management of anticoagulation during noncardiac operations in patients with prosthetic heart valves. A prospective study. Am Heart J 1978; 96:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/41\">",
"      Spyropoulos AC, Frost FJ, Hurley JS, Roberts M. Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy. Chest 2004; 125:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/42\">",
"      Kovacs MJ, Kearon C, Rodger M, et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 2004; 110:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/11/18618/abstract/43\">",
"      Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:299S.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8171 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-199.231.185.123-B6CE745EC8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_11_18618=[""].join("\n");
var outline_f18_11_18618=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21687972\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4298892\">",
"      Warfarin and aspirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4298909\">",
"      Oral direct thrombin inhibitors and factor Xa inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANICAL VALVES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Warfarin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Warfarin plus aspirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mechanical valve recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Early anticoagulation post mechanical valve replacement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      BIOPROSTHETIC VALVES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Bioprosthetic valve long-term recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Initiation of anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Early thromboembolic risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Evidence of early risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Early anticoagulation after bioprosthetic valve replacement or mitral valve repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2835682\">",
"      VALVE REPAIR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SPECIAL CIRCUMSTANCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Elderly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Thromboembolism despite antithrombotic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      BLEEDING AND CORRECTION OF OVERANTICOAGULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      INTERRUPTION OF WARFARIN FOR SURGICAL PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      General considerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2836061\">",
"      - Standardized perioperative procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Role of bridging anticoagulation with heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Major guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Choice of heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Patients with high thromboembolic risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Patients with low thromboembolic risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      INTERRUPTION OF WARFARIN FOR CARDIAC CATHETERIZATION/ANGIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21687972\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8171\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8171|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/18/43296\" title=\"figure 1\">",
"      Events in AF according to INR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8171|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/58/11181\" title=\"table 1\">",
"      FDA approved prosthetic valves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/45/24284\" title=\"table 2\">",
"      ACC AHA Rx mechanical valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/7/18556\" title=\"table 3\">",
"      ACCP Rx mechanical valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/10/172\" title=\"table 4\">",
"      ESC Rx mechanical valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/5/6236\" title=\"table 5\">",
"      ACC AHA Rx bioprosthetic valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/49/2844\" title=\"table 6\">",
"      ACCP Rx bioprosthetic valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/44/41676\" title=\"table 7\">",
"      ACC AHA bridging therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/32/24076\" title=\"table 8\">",
"      ESC bridging therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/14/1258?source=related_link\">",
"      Anticoagulation in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=related_link\">",
"      Complications of prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=related_link\">",
"      Correcting excess anticoagulation after warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21014?source=related_link\">",
"      Management of anticoagulants in patients undergoing endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=related_link\">",
"      Management of anticoagulation before and after elective surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15238?source=related_link\">",
"      Management of patients with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1882?source=related_link\">",
"      Management of pregnant women with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10298?source=related_link\">",
"      Management of warfarin-associated intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35880?source=related_link\">",
"      Outpatient management of oral anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/23/11635?source=related_link\">",
"      Patient information: Prosthetic valves (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=related_link\">",
"      Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/29/34264?source=related_link\">",
"      Transcatheter aortic valve replacement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/36/34377?source=related_link\">",
"      Valvular heart disease in elderly adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_11_18619="Therapies for DES and hypercontracting motility abnormalities";
var content_f18_11_18619=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Possible therapies for diffuse esophageal spasm and hypercontracting motility abnormalities",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Supported by clinical trials",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium channel blockers (eg, diltiazem)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antidepressants (eg, trazodone, imipramine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Positive anecdotal results",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nitrates (eg, nitroglycerine, isosorbide dinitrate)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anticholinergic drugs (eg, dicyclomine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bougie dilatation (17 to 20 mm diameter)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Botulinum toxin injection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phosphodiesterase inhibitors (eg, sildenafil)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Minimal clinical support and greater potential for adverse effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumatic dilatation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Esophagomyotomy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_11_18619=[""].join("\n");
var outline_f18_11_18619=null;
var title_f18_11_18620="Uncommon causes of syncope";
var content_f18_11_18620=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major uncommon causes of syncope",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cardiovascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Arrhythmic causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Supraventricular tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Long QT interval syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Idiopathic ventricular tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Myocardial infarction causing bradycardias and tachycardias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Right ventricular dysplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Nonarrhythmic causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pulmonary embolus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pulmonary hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dissecting aortic aneurysm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Subclavian steal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Atrial myxoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cardiac tamponade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Noncardiovascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Reflexes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Defecation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Glossopharyngeal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Postprandial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Carotid sinus hypersensitivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperventilation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anaphylaxis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Migraine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carcinoid syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic mastocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Metabolic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypoglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypoxia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multivessel obstructive cerebrovascular disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_11_18620=[""].join("\n");
var outline_f18_11_18620=null;
var title_f18_11_18621="Vasa recta flow";
var content_f18_11_18621=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F72439&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F72439&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vasa recta flow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 295px; height: 244px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Principle of countercurrent exchange in the vasa recta capillaries. In the descending capillary limb, there is passive diffusion of sodium and urea into (solid arrows) and water diffusion out of (dashed arrows) the capillary down concentration gradients, tending to reduce interstitial osmolality. These processes are reversed in the ascending capillary limb, thereby preserving the interstitial osmolal gradient. The numbers represent the appropriate osmolality in the tubular lumen and interstitium at different levels of the capillary.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Pitts, RF, Physiology of the Kidney and Body Fluids, 3d ed, Capyright 1974 by Year Book Medical Publishers, Inc, Chicago. Used by permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_11_18621=[""].join("\n");
var outline_f18_11_18621=null;
var title_f18_11_18622="Outcome saphenous vein stent";
var content_f18_11_18622=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78527&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78527&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Long-term outcome of saphenous vein graft stenting",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 256px; height: 489px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Compared to native vessel stenting, the probability of requiring any revascularization (upper panel) or revascularization of non-target sites (non-TSR, middle panel) is higher for saphenous vein graft stenting. However, the probability of revascularization of a target site is similar for stents placed in native vessels and saphenous grafts (lower panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Laham RJ, Carrozza JP, Berger C, et al. J Am Coll Cardiol 1996; 28:820.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_11_18622=[""].join("\n");
var outline_f18_11_18622=null;
var title_f18_11_18623="Emergent evaluation of pediatric headache";
var content_f18_11_18623=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 572px\">",
"   <div class=\"ttl\">",
"    Headache in child with no immunocompromise, no shunt, and no known trauma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 552px; height: 527px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CSF: cerebrospinal fluid; BP: blood pressure.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_11_18623=[""].join("\n");
var outline_f18_11_18623=null;
